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Role of Sodium Arsenite in Atherogenesis
Chairperson: Howard D. Beall
Epidemiological studies as well as controlled animal studies have associated exposure to
arsenic through drinking water with the development of atherosclerosis. In this study, we
have shown for the first time that low and environmentally relevant concentrations of
arsenic accelerate atherogenesis. The objective of this study was to elucidate the
mechanisms of arsenic-induced atherosclerosis by (1) characterizing the time- and
concentration-dependent effects of sodium arsenite [As(III)] on the development of
atherosclerosis in ApoE-/- /LDLr-/- mice, (2) determining whether As(III)-induced
peroxynitrite activates protein kinase C (PKC) isotypes, α and β, in human aortic
endothelial cells (HAECs) and (3) determining the effects of activation of PKC isotypes,
α and β, on the endothelial barrier. Accordingly, exposure of ApoE-/- /LDLr-/- mice to
As(III) in drinking water showed an increasing trend in atherosclerotic plaque formation
in as early as 5 weeks within the innominate arteries. Most remarkable was the evidence
that environmentally relevant concentrations of As(III) resulted in significant increase in
plaque formation. Initiation of atherosclerosis results from activation/dysfunction of the
vascular endothelium that maintains a semipermeable barrier between the blood and
vessel wall. To elucidate the mechanism of arsenic-induced atherosclerosis, we analyzed
the effect of As(III) on the endothelial monolayer integrity. Endothelial barrier is
maintained by proteins of the adherens junction (AJ) such as vascular endothelial
cadherin (VE-cadherin) and β-catenin, and their association with the actin cytoskeleton.
Treatment of HAECs with As(III) resulted in reorganization of actin filaments into stress
fibers and non-uniform VE-cadherin and β-catenin staining at cell-cell junctions.
Intercellular gaps were observed with a measured increase in endothelial permeability. In
addition, an increase in tyrosine phosphorylation (PY) of β-catenin was observed. These
effects were mediated through As(III)-induced activation of PKCα without peroxynitrite
formation. No change in PKCβ levels was detected with As(III) treatment. Inhibition of
PKCα restored VE-cadherin and β-catenin staining at cell-cell junctions and abolished the
formation of intercellular gaps and stress fibers. Endothelial permeability and PY of βcatenin were also reduced to basal levels. These results demonstrate that As(III) induced
activation of PKCα causes PY of β-catenin and formation of stress fibers. PY of βcatenin causes weakening of the AJ and this in association with the contractile force
generated by stress fibers results in gap formation and increased endothelial permeability.
This could potentially accelerate the development of atherosclerosis by increasing the
accumulation of oxidized low density lipoproteins and monocytes into the neo-intima of
the blood vessel. The findings in this study demonstrate that arsenic disrupts the
endothelial monolayer by activation of PKC signaling. Damage to the endothelium
plausibly accelerates the process of atherosclerosis at an early stage as evidenced by the
increase in atherosclerotic plaques in the ApoE-/- /LDLr-/- mouse model.
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Chapter 1
Introduction

1.1

Rationale
Millions of people worldwide are exposed to arsenic through drinking water that

has been associated with the development of cardiovascular diseases such as carotid
atherosclerosis, ischemic heart disease and hypertension. Atherosclerosis is the
fundamental cause of major cardiovascular diseases including ischemic heart disease,
myocardial infarction and stroke. The focus of our laboratory has been to elucidate the
mechanisms of arsenic-induced cardiovascular disease. The objective of this study was to
determine the effects of arsenic on endothelial cell biology and the development of
atherosclerosis. The in vivo effects of environmentally relevant concentrations of arsenic
in atherogenesis were analyzed using the ApoE-/- /LDLr-/- mouse, which is a wellestablished model of human atherosclerosis. The in vitro studies focused on determining
the mechanism of arsenic-induced atherosclerosis by using human aortic endothelial
cells. The research presented here lends a valuable contribution towards understanding
the role of arsenic in cardiovascular toxicity and will aid in developing future treatment
and prevention strategies.
Specific Aim 1: Characterize the time- and concentration-dependent effects of As(III) on
the initiation and progression of atherosclerosis in ApoE-/- /LDLr-/- atherosclerotic
mouse model.
Specific Aim 2: Determine the effects of As(III)-induced peroxynitrite on the activation
of calcium-dependent cPKC isotypes, α and β, in human aortic endothelial cells.
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Specific Aim 3: Determine whether activation of the cPKC isotypes, α and β, by As(III)
is involved in endothelial barrier disruption.

1.2

Cardiovascular Disease

1.2.1

Statistics
Cardiovascular disease (CVD) is the number one killer in the United States as

well as developed Western countries. According to current estimates from the American
Heart Association (Heart Disease and Stroke Statistics, 2007 update), about 80 million
Americans have one or more types of CVD. The percentage breakdown of deaths from
CVD is coronary heart disease (52%), stroke (17%), heart failure (7%), high blood
pressure (6%), disease of arteries (4%), congenital cardiovascular defects (0.5%),
rheumatic heart disease (0.4%) and other (13%). Atherosclerosis is the underlying cause
of major clinical cardiovascular events.

1.2.2

Risk Factors
The American Heart Association has identified several risk factors for CVD based

on extensive clinical and statistical studies. Some of the risk factors can be controlled
through adequate lifestyle changes and/or use of medication, whereas others cannot be
controlled. The controllable risk factors include cigarette smoking, high blood pressure,
high blood cholesterol, diabetes mellitus, physical inactivity and obesity. The
uncontrollable risk factors include increasing age, gender and heredity. Other risk factors
have been associated with CVD, but their significance and prevalence are yet to be

2

confirmed. These factors are known as ‘contributing risk factors’ and include stress and
excessive alcohol intake.

1.2.3

Atherosclerosis
Atherosclerosis is a complex, progressive and multifactorial disease characterized

by deposition of lipid and fibrous elements in the subendothelial space. It is the
underlying cause of serious clinical manifestations such as ischemic heart disease,
myocardial infarction and stroke.
The normal large artery consists of three layers; the intima, media and adventitia
(Fig. 1). The intima, the innermost layer, consists of extracellular connective tissue
matrix, primarily collagen and proteoglycans. The intima is bounded by the endothelial
monolayer on luminal side and elastic lamina on the peripheral side. The media, the
middle layer, consists of smooth muscle cells. The adventitia is the outermost layer and
consists of connective tissue with interspersed fibroblast and smooth muscle cells (Lusis,
2000). An initiating event in the development of an atherosclerotic lesion or fatty streak
is the accumulation of oxidized low density lipoproteins (oxLDLs) into the intima of
blood vessel. The oxLDLs stimulate the overlying endothelial cells to express cell
adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and
intercellular cell adhesion molecule-1 (ICAM-1), proinflammatory cytokines such as
interleukin-1 (IL-1) and IL-6, and chemokines such as monocyte chemottractant protein1 (MCP-1) and IL-8 (Tedgui and Mallat, 2006) (Fig. 2). The VCAM-1 expressed by
endothelial cells play a major role in transmigration of monocytes from the blood into the
intima (Cybulsky et al., 2001, Nakashima et al., 1998) along with MCP-1 (Libby, 2002).
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Once inside the intima, the monocytes differentiate into macrophages and internalize
oxLDLs resulting in the formation of lipid laden foam cells. The activated macrophages
further secrete proinflammatory cytokines such as tumor necrosis factor α (TNFα), IL-1,
and IL-6, and chemokines such as IL-8 and MCP-1 that in turn can activate endothelial
cells, smooth muscle cells (SMC) and resident macrophages leading to a selfperpetuating inflammatory process (Tedgui and Mallat, 2006).
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Fig. 1. Structure of a normal large artery
Reprinted by permission from Macmillan Publishers Ltd: Nature; Lusis, 2000, © 2000
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Fig. 2. Development of atherosclerotic lesion.
Reprinted by permission from Macmillan Publishers Ltd: Nature; Libby, 2002, © 2002
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Accordingly, it has been observed that stimulation of endothelial cells from
different vascular beds such as human aortic endothelial cells (HAEC), human coronary
artery endothelial cells (HCAEC) or human heart microvascular endothelial cells
(HHMEC) with proinflammatory cytokines, TNFα and IL-1β, upregulates the expression
of VCAM-1 (McDouall et al., 2001). Co-culture experiments of endothelial cells with
human peripheral blood mononuclear cells (PBMC) revealed increased binding of PBMC
to TNFα stimulated endothelial cells, implying that the increased expression of VCAM-1
may increase adhesion to the endothelium and transmigration of monocytes into the
blood vessel intima during inflammatory conditions (McDouall et al., 2001). Consistent
with this, using an en face imaging technique, Nakashima et al. (1998) reported that in
apolipoprotein E deficient (ApoE-/-) mice, VCAM-1 is upregulated at the lesion-prone
sites by hypercholesterolemia. The authors concluded that VCAM-1 expression is an
early event that precedes fatty streak formation and may play a critical role in monocyte
recruitment from the blood. Also, elevated levels of soluble VCAM-1 have been detected
in the plasma of patients with coronary heart disease and myocardial infarction compared
to healthy subjects (Zeitler et al., 1997).
During the progression of an atherosclerotic lesion there is accumulation of
excessive lipid, multiplying SMCs and SMC-derived extracellular matrix, especially
collagen. The developing plaque consists of a core, fibrous cap covering the plaque and
the shoulder region (Lusis, 2000). Composition of the plaque determines its stability.
Vulnerable plaques generally have thin fibrous cap, decreased collagen content and
increased number of lipid laden macrophages in the shoulder region. The matrix
metalloproteinases (MMP), collagenase, gelatinase and stromolysin, secreted by the
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activated macrophages can cause thinning of the fibrous cap by degrading the collagen
content of the extracellular matrix. This can make the atherosclerotic plaques more
vulnerable to rupture. Inflammatory cytokines also play a significant role in plaque
instability and rupture. Cytokines such as TNFα and IL-1β have been shown to stimulate
the production of 92 kDa gelatinase in macrophages without affecting tissue inhibitor of
metalloproteinases-1 (TIMP-1), which is their natural inhibitor (Saren et al., 1996).
Increased IL-6 levels have been strongly correlated with atherosclerotic plaque
instability and rupture in human subjects. In the left anterior descending coronary artery
obtained from patients with ischemic cardiomyopathy, atherosclerotic plaques showed
co-localization of IL-6 with macrophages in the shoulder region (Schieffer et al., 2000).
The lipid-rich shoulder areas of plaques are the most vulnerable sites of plaque rupture
(van der Wal et al., 1994, Schieffer et al., 2000). Similarly, Cheng et al. (2006)
demonstrated increased expression of IL-6 in macrophage-rich areas of atherosclerotic
plaques in ApoE-/- mice along with increased MMP activity. The authors suggested that
IL-6 causes the increase in macrophage MMP activity that contributes to weakening of
the fibrous cap and increased potential of plaque rupture. Increased plasma levels of IL-6
have been detected in patients with acute myocardial infarction, coronary artery disease
and peripheral artery disease (Erren et al., 1999, Ikeda et al., 1992). Rupture of plaques
can generate circulating blood clots, when blood coming in contact with the tissue factor
in the plaque coagulates (Libby, 2002). These clots can result in occlusion of blood
vessels leading to ischemia, myocardial infarction or stroke.
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1.2.4

Mouse models of Atherosclerosis
Numerous animal species have been used to study the pathogenesis of

atherosclerosis. These include pigeons, hamsters, rabbits, pigs and monkeys. However,
several factors such as costs of maintenance and/or dissimilar disease progression status
compared to humans have limited their use (Jaweiń et al., 2004). In recent years, the
mouse has become a most useful model in the study of atherosclerosis. The low cost of
maintenance, ease of breeding and genetic manipulation have made it the model of choice
among biomedical researchers.
The most commonly used mouse models in the study of atherosclerosis are low
density lipoprotein receptor deficient mice (LDLr-/-), the ApoE-/- mice, and the
apolipoprotein E and low density lipoprotein receptor (ApoE-/- /LDLr-/-) double
knockout mice (Jaweiń et al., 2004, Daugherty, 2002). Mice are highly resistant to
atherosclerosis and the lipid profile differs from that in humans. Mice carry most of the
plasma cholesterol on high density lipoprotein (HDL), whereas humans carry 75% of
cholesterol on low density lipoprotein (LDL) (Jaweiń et al., 2004). However, targeted
gene deletion has enabled the generation of mouse models that develop atherosclerosis
and have lipid profiles similar to humans.
ApoE is a 34 kD glycoprotein that is synthesized mainly by the liver. It is also
produced by other tissues such as brain, spleen, lung, ovary, adrenal gland, kidney and
muscles, and by cells types such as macrophages (Greenow et al., 2005). There are 3
isoforms of ApoE; ApoE2, E3 and E4. The e3 allele is present in the majority of
population. People with familial hypercholesterolemia have two copies of the e2 allele.
ApoE is a major constituent of very low density lipoprotein (VLDL), but is also present
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in HDL and chylomicron remnants. It promotes hepatic clearance of cholesterol by acting
as a high affinity ligand for the hepatic LDL receptor. ApoE also binds another hepatic
receptor, LDL receptor related protein (LRP), and has been implicated in the clearance of
chylomicron remnants (Greenow et al., 2005). Other anti-atherogenic functions of ApoE
include inhibition of LDL oxidation, inhibition of platelet aggregation, inhibition of SMC
and endothelial cell proliferation and cholesterol efflux from macrophages. The hepatic
LDL receptor, in addition to recognizing lipoproteins containing ApoE, is also
responsible for the uptake of LDLs via interaction with ApoB-100. The ApoB-100 is an
exclusive apolipoprotein associated with LDLs (Olofsson and Boren, 2005). Thus, the
LDL receptor plays an important role in removal of excessive blood cholesterol. The
increase in circulating LDLs is a risk factor for CVD.
The ApoE-/- mice develop atherosclerotic lesions/plaques that closely resemble
the human condition. The development of plaques in the innominate artery of this mouse
model has been well characterized and has been shown to closely resemble that of human
condition with events such as intraplaque hemorrhage and loss of fibrous cap or plaque
rupture (Rosenfeld et al., 2000). A major limitation of the ApoE-/- mouse model is that
the lipid profiles are dissimilar from that of human subjects. In these mice, the plasma
cholesterol is carried on VLDL (Ishibashi et al., 1994, Daugherty, 2002, Ohashi et al.,
2004), whereas in human subjects with atherosclerosis the majority of plasma cholesterol
is carried on LDLs. On the other hand, the lipid profiles of LDLr-/- mouse model are
more similar to that of human subjects with the majority of plasma cholesterol being
carried on LDL and VLDL (Ishibashi et al., 1994, Jaweiń et al., 2004, Ohashi et al.,
2004). However, these mice develop lesions that consist of primarily lipid-laden
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macrophages and lack advanced atherosclerotic lesions. Only when fed with high fat diet
for longer periods do these mice develop advanced atherosclerotic lesions (Daugherty,
2002, Ohashi et al., 2004). Compared to ApoE-/- or LDLr-/- mice alone, the ApoE-//LDLr-/- mice develop more marked atherosclerotic plaques (Jaweiń et al., 2004). The
lipid profiles of this mouse model are more similar to that of humans as compared to
either ApoE-/- or LDLr-/- mice, with the majority of plasma cholesterol being carried on
LDLs when fed with normal mouse chow (Ishibashi et al., 1994). This makes the ApoE-//LDLr-/- mouse an ideal model to study the progression of atherosclerosis.

1.3

Arsenic

1.3.1

Environmental Significance of Arsenic
Arsenic is a ubiquitous element in the environment present in rocks and soil, air

and natural water. Exposure to arsenic via drinking water poses a significant threat to
human health. Contamination of ground water occurs by mobilization of arsenic under
natural conditions. Arsenic occurs as a major constituent in several minerals such as
sulphides and oxides. Three mechanisms have been identified that result in arsenic
mobilization under geochemical conditions (Smedley and Kinniburgh, 2002, Delemos et
al., 2006). First, in arid or semi-arid environments, mineral weathering and high
evaporation rates can result in development of high pH (>8.5) conditions that can cause
desorption of adsorbed arsenic from mineral oxides or prevent it from being adsorbed.
Second, strong reducing conditions result in the reductive dissolution of oxides such as
iron and manganese, and release of arsenic by desorption. Third, competitive desorption

11

of arsenic by the presence of large concentrations of phosphate, bicarbonate and silicates
can lead to increased ground water contamination with arsenic.
In addition to the natural existence, arsenic is also widely distributed in the
environment by human activities such as mining, smelting, pesticide application and
manufacturing and use of products such as wood preservatives and dyes. In the United
States, improper waste management from industrial and municipal sources, has created
contaminated areas termed as ‘Superfund Sites’ that contain extremely high and
dangerous levels of several environmental contaminants including arsenic. About 30% of
the Superfund Sites in United States have excessive arsenic levels (Welch et al., 2000).
Some of the sites have arsenic contamination introduced from human activities but many
of the sites do not have a known source of contamination. A recent study performed at
the Coakley Landfill Superfund Site in New Hampshire, a site contaminated with arsenic,
chromium, lead, nickel, zinc and aromatic hydrocarbons, has reported that the
concentrations of most of the contaminants diminished as a result of treatment by
monitored natural attenuation that began in 1998, but the levels of dissolved arsenic
increased over the same time interval (Delemos et al., 2006). This was due to the
reductive release of arsenic from iron oxides. Natural biogeochemical processes are used
to degrade contaminants. However, reducing environments created due to biodegradation
of organic waste can cause the release of adsorbed arsenic from mineral oxides (Delemos
et al., 2006). Although, this problem has only been identified in New Hampshire thus far,
it could be a major problem all across the United States or in other countries where
arsenic concentration in ground water is higher than the standard implemented by World
Health Organization (WHO).
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In the United States, the western regions have higher arsenic contamination of
ground water (10 to >50 ppb) than the eastern regions (<10 ppb). However, there may be
geographic ‘hotspots’ in the regions that have higher arsenic levels. In February 2002, the
United States Environmental Protection Agency implemented the maximum contaminant
limit (MCL) of 10 ppb for arsenic. The public water supply systems had to comply with
this new standard by January 2006. Arsenic contamination of ground water is a
worldwide problem. In 1993, the WHO also implemented the MCL of 10 ppb. In addition
to the United States, Taiwan, Bangladesh, India (West Bengal), China, Vietnam,
Hungary, Mexico, Romania and Argentina have high levels of arsenic in ground water
ranging from 10-14,000 ppb (Wang and Wai, 2004, Smedley and Kinniburgh, 2002).

1.3.2

Metabolism of Arsenic
Exposure to arsenic can occur via food, water and air, of which drinking water

(ground water) is a significant source of arsenic exposure in humans. Natural waters
including drinking water mostly contain inorganic arsenic species; trivalent arsenite
[As(III)] and pentavalent arsenate [As(V)] (Smedley and Kinniburgh, 2002).
Concentrations of organic forms of arsenic are generally low or negligible in drinking
water, but may occur in waters severely affected by industrial pollution (Smedley and
Kinniburgh, 2002). The metabolism of arsenic in most mammals involves a series of
reduction and oxidative methylation reactions during which As(V) is reduced to As(III)
that is further metabolized to methylated species (Abernathy et al., 1999). The major site
of arsenic methylation is the liver and the route of excretion is via the kidneys. There is
considerable variation in arsenic methylation among mammalian species (Vahter, 2000).
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As(V) and As(III) are the major forms of inorganic arsenic present in drinking
water. The mechanism of cellular uptake of arsenic varies with the valence state. As(V) is
structurally similar to phosphate and its uptake into the cells is mediated through the
phosphate carrier system (Huang and Lee, 1996). Two different mechanisms have been
proposed for the cellular uptake of As(III); simple diffusion (Huang and Lee, 1996) and
transport by mammalian aquaglyceroporins (Liu et al., 2002). As(V) has been shown to
compete with phosphate and can deplete cellular energy levels by preventing the
incorporation of phosphate into adenosine 5’-triphosphate (ATP). As(III) on the other
hand is extremely thiol reactive and can affect the activities of several enzymes
(Aposhian et al., 2004). The first step in the metabolism of arsenic involves the reduction
of As(V) to As(III) by arsenate reductase in the presence of glutathione (GSH). The
sulfhydryl-containing tripeptide, GSH, forms As(III)-(GS)3 complexes that may be
substrates for methylating enzymes (Scott et al., 1993). Recent in vitro and in vivo studies
using a rat model suggest that the key glycolytic enzyme, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), is the arsenate reductase enzyme in mammals (Neméti and
Gregus, 2005, Gregus and Neméti, 2005, Neméti et al., 2006). However, further studies
are needed to confirm this observation.
The next step in the metabolism of arsenic consists of a series of methylation
reactions. As(III) is methylated to the pentavalent species, monomethyl arsonic acid
[MMA(V)], by arsenite/MMA(III) methyltransferase in the presence of GSH. Sadenosylmethionine (SAM) is the methyl donor in the methylation reactions (Buchet and
Lauwerys, 1988). Using methyltransferases of rabbit liver, it has been shown that the
arsenite methyltransferase and MMA(III) methyltransferase appear to have common
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properties or may be part of the same protein or multienzyme complex (Zakharyan et al.,
1995). Furthermore, studies have reported that rat liver arsenite methyltransferase is a
homologue of human cyt19 (Lin et al., 2002, Thomas et al., 2004). Recombinant rat and
human cyt19 has been shown to methylate inorganic arsenite in in vitro conditions
(Waters et al., 2004, Hayakawa et al., 2005). However, the expression and enzymatic
activity of cyt19 in human liver has yet to be confirmed (Aposhian and Aposhian, 2006).
The first methylation step is followed by alternating reduction of pentavalent arsenic to
trivalent arsenic with the addition of a methyl group (Fig. 3). MMA(V) reductase in the
presence of GSH catalyzes the reduction of MMA(V) to monomethylarsonous acid
[MMA(III)] (Zakharyan and Aposhian, 1999) that is further oxidatively methylated to
dimethylarsinic acid [DMA(V)] in the presence of arsenite/MMA (III) methyltransferase.
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Fig. 3. Classical metabolic pathway of inorganic arsenic.
Adapted from Hayakawa et al., 2005.
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In vitro studies have proposed the existence of As(III)-(GS)3 complexes (Scott et
al., 1993). Kala et al. (2000) showed that arsenic-glutathione complexes are excreted in
bile using the rat as in vivo animal model. This study detected the presence of arsenic
triglutathione (ATG) and methylarsonic diglutathione (MADG) in bile samples. Based on
these studies, a new metabolic pathway for inorganic arsenic has been proposed
(Hayakawa et al., 2005) (Fig. 4). According to this pathway, As(V) is reduced to As(III)
as described previously in the original pathway. As(III) complexes with GSH in the
presence of SAM and cyt19 to form ATG that in turn acquires 2 methyl groups forming
MADG and dimethylarsinic glutathione (DMAG), respectively. MADG is then
hydrolyzed to MMA(III), which is further oxidized to MMA(V). Similarly, DMAG is
converted to DMA(V). This new pathway is in its infancy and additional studies will be
needed to confirm the reaction steps. Also, the formation of various intermediates in this
pathway has been demonstrated in in vitro conditions and needs further in vivo
confirmation (Thomas et al., 2007, Aposhian and Aposhian, 2006).
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Fig. 4. New metabolic pathway of inorganic arsenic
Adapted from Hayakawa et al., 2005.
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The bulk of data on metabolism of arsenic has been obtained from in vitro cellfree studies using rat liver cytosol, purified arsenic methyltransferase enzyme or rat
hepatocytes. Styblo et al. (1999) documented the metabolism of arsenic using primary
human hepatocytes. According to this study, human hepatocytes exposed to As(III)
showed a steady decline in As(III) in the culture medium with simultaneous increase in
MMA and DMA species. The formation of DMA accounted for 60% of the arsenic in the
culture medium. In contrast, exposure of human hepatocytes to As(V) resulted in the total
methylation yield (MMAs and DMAs) of less than 3%, probably due to the lower uptake
of As(V) by hepatocytes (Styblo et al., 1999). However, it has been shown that majority
of the ingested As(V) is rapidly reduced to As(III), probably in the blood (Vahter, 2002).
Therefore, As(III) could be the major inorganic arsenic species metabolized by liver
hepatocytes.
In mammals, liver is the primary organ for arsenic methylation. Other organs such
as kidneys, lungs and testes also have arsenic methylating activity (Vahter, 2002). The
major route of arsenic excretion is via the kidneys. MMA(V) and DMA(V) are the main
metabolites found in the urine of humans exposed to arsenic. Variation in arsenic
methylation between different populations groups have been reported based on the
metabolites analyzed in urine samples (Vahter, 2002). Several factors such as age,
gender, nutrition and polymorphisms in genes regulating the methyltransferases have
been suggested to play a role in the inter-individual variation in arsenic metabolism.
Irrespective of the arsenic concentration and the extent of exposure, on average, the
human urine contains 10-30% inorganic arsenic, 10-20% MMA(V) and 60-80%
DMA(V) (Vahter, 2000, Vahter, 2002). Considerable variation in the methylation of
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arsenic has been reported among other mammalian species (Vahter, 1994). Compared to
human subjects, animal species such as rat, mouse, dog, rabbit and hamster excrete very
little MMA(V). The excretion of DMA(V) and inorganic arsenic also differs between
species. Interestingly, the marmoset monkey and the chimpanzee lack the ability to
methylate arsenic (Vahter, 1994, Vahter, 2000). This points out the species specific
differences in the arsenic methylating enzymes and therefore, the results of arsenic
metabolism studied using different species should be interpreted with caution.

1.3.3

Arsenic and Reactive Species
As(III) (<5 μM) has been shown to produce reactive oxygen species (ROS)

including superoxide anion and hydrogen peroxide, but not reactive nitrogen species
(RNS) such as nitric oxide in porcine aortic endothelial cells (Barchowsky et al., 1999).
Increased levels of plasma superoxide have been positively correlated with arsenic
concentration in whole blood of human subjects exposed to high arsenic levels in
northeastern Taiwan (Wu et al., 2001). As(III) (>5 μM) has been shown to increase levels
of nitric oxide in bovine aortic endothelial cells (Lynn et al., 1998; Liu and Jan, 2000).
Furthermore, As(III) (>0.25 μM) has been shown to generate the RNS, peroxynitrite, in
bovine aortic endothelial cells (Bunderson et al., 2002). Peroxynitrite is formed by the
rapid reaction of superoxide with nitric oxide and is a strong oxidizing and nitrating
molecule. Peroxynitrite can induce protein modifications via oxidation/nitration of
cysteine, tyrosine, methionine and tryptophan residues (Pryor and Squadrito, 1995, Radi
et al., 2001, Beckman, 1996). Formation of peroxynitrite can cause lipid peroxidation
(Radi et al., 1991), generate oxLDLs (Keaney, 2000) and activate nuclear factor-kappa B
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(NF-κB) (Cooke and Davidge, 2002, Matata and Galinanes, 2002). Peroxynitrite has been
reported to interfere with cellular processes and signal transduction pathways by
oxidation as well as nitration of proteins (Klotz et al., 2002). The detection of
nitrotyrosine in biological samples has been used as a marker for the presence of
peroxynitrite (Ischiropoulos, 1998, Beckman and Koppenol, 1996). The presence of
nitrotyrosine has been observed in human atherosclerotic plaques (Beckman et al., 1994,
Cromheeke et al., 1999). Also, nitrotyrosine formation has been detected in the
atherosclerotic plaques of ApoE-/- /LDLr-/- mice exposed to As(III) in drinking water
(Bunderson et al., 2004).
Contradictory to the increase in nitric oxide production in endothelial cells, it was
observed that Chinese individuals exposed to arsenic in drinking water had reduced
serum levels of nitric oxide metabolites indicating impaired nitric oxide generation (Pi et
al., 2000). This observation was confirmed in rabbits exposed to 5 ppm As(V) in drinking
water for 18 weeks (Pi et al., 2003). As(V) or As(III) (100 μM) were shown to suppress
the activity of endothelial nitric oxide synthase (eNOS), the enzyme responsible for
catalyzing production of nitric oxide, in the homogenates of human umbilical vein
endothelial cells (HUVEC) (Pi et al., 2000). It was also observed that treatment of
HAECs with As(III) (>10 μM) reduced eNOS activity, thereby suppressing nitric oxide
production (Lee et al., 2003). However, Kao et al. (2003) demonstrated that As(III) (<5
μM) induces an increase in eNOS protein synthesis and production of nitric oxide in
HUVECs. Therefore, it appears that the production of reactive species with arsenic
treatment differs with the experimental conditions such as cell line in consideration and
concentration of arsenic.
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1.3.4

Arsenic and Cardiovascular Disease
Epidemiological studies have associated arsenic exposure with the development

of CVDs. In the United States, a study conducted in 30 counties investigated the
ecological relationship between population-weighted mean arsenic concentration in
public water supplies and mortality from vascular disease from 1968 to 1984 (Engel and
Smith, 1994). According to this study, exposure to arsenic levels greater than 20 ppb
were associated with increased mortality from various CVDs such as coronary heart
disease, peripheral arterial diseases and stroke (Engel and Smith, 1994, Navas-Acien et
al., 2005). In Bangladesh, where the arsenic concentration is ground water ranges from
10-14,000 ppb (Wang and Wai, 2004), a study was conducted to determine the
relationship between arsenic exposure and development of hypertension. After adjusting
for age, sex and body mass index, a significant dose-response relationship was observed
between concentration of arsenic in drinking water and prevalence of hypertension
(Rahman et al., 1999). Arsenic exposure through drinking water has also been associated
with the development of ischemic heart disease and carotid atherosclerosis based on
studies conducted in Taiwan, where arsenic levels range from 100-1810 ppb (Wang and
Wai, 2004). Wang et al. (2002) documented the effect of long-term arsenic exposure and
extent of carotid atherosclerosis. By adjusting for the risk factors of atherosclerosis
including age, sex, hypertension, diabetes mellitus, cigarette smoking, alcohol
consumption, waist-to-hip ratio and cholesterol, a significant association was observed
between arsenic exposure and prevalence of carotid atherosclerosis. A dose-response
relationship was observed between the prevalence of carotid atherosclerosis and each of
the three indices of arsenic exposure; duration of consumption of arsenic contaminated
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water, average arsenic concentration in water and cumulative arsenic exposure (Wang et
al., 2002). Atherosclerosis is the underlying cause of CVDs including ischemic heart
disease. Tseng et al. (2003) documented the association of long-term arsenic exposure
with ischemic heart disease. After adjusting for risk factors, prevalence rates for ischemic
heart disease positively correlated with cumulative arsenic exposure (arsenic
concentration in drinking water and duration of exposure) of 0.1 to > 15 mg/l-year. Thus,
epidemiological studies strongly associate arsenic exposure with development of CVD.
Several confounding factors can obscure or underestimate the severity of arsenic
effects. For example, a majority of epidemiological studies have taken into account
arsenic exposure through drinking water, but have not accounted for exposure due to
other sources such as contaminated food or cooking water (Navas-Acien et al., 2005).
Controlled animal studies have helped eliminate the confounding factors and confirm the
association between high levels of arsenic exposure and development of CVD. It has
been observed that exposure to 20 and 100 ppm As(III) in drinking water for 24 weeks
accelerates atherogenesis in ApoE-/- mice (Simeonova et al., 2003). Our laboratory has
previously demonstrated that chronic exposure (18 weeks) to 10 ppm As(III) in drinking
water exacerbates atherosclerotic plaque formation in ApoE-/- /LDLr-/- mice (Bunderson
et al., 2004). In addition, As(III) exposure has been documented to cause blood vessel
dysfunction in a rat model. It was observed that intravenous injection of 1 mg/kg As(III)
solution suppressed the acetylcholine-induced reduction of blood pressure (Lee et al.,
2003) and augmented the phenylephrine-induced increase in blood pressure (Lee et al.,
2005) in conscious male Sprague-Dawley rats. Thus, As(III) exposure possibly impairs
vascular homeostasis and thereby contributes to the development of CVDs.
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The vascular endothelium plays a critical role in the atherosclerotic disease
process. In vitro and in vivo studies suggest that arsenic can modulate the inflammatory
mediators involved in the process of atherosclerosis, generate oxidative and nitrosative
stress and cause transcription factor activation and gene expression relevant to
endothelial dysfunction. It has been observed that treatment of HAECs with 5 or 50 μM
As(III) induces IL-8 gene expression with simultaneous increase in AP-1 and NF-κB
DNA binding activity (Simeonova et al., 2003). Expression of the inflammatory
mediator, IL-8, is regulated by the transcription factors AP-1 and NF-κB. Oxidantsensitive activation of NF-κB has been documented in porcine aortic endothelial cells
exposed to 2-5 μM As(III) (Barchowsky et al., 1996). In addition, As(III) (>5 μM) has
been shown to increase the expression of inflammatory mediators such as
cyclooxygenase-2 (Bunderson et al., 2002) and leukotriene E4 (Bunderson et al., 2004) in
bovine aortic endothelial cells as well as ApoE-/- /LDLr-/- mice exposed to 10 ppm
As(III) for 18 weeks. As(V) and As(III) have also been related to the impairment of nitric
oxide production in the vasculature as described previously in section 1.3.3 (Lee et al.,
2003, Pi et al., 2003). Nitric oxide plays an important role in vascular homeostasis. This
may contribute to arsenic-related hypertension as well as atherosclerosis. As(III) (>10
μM) has also been shown to cause platelet aggregation and thrombus formation (Lee et
al., 2002). Thrombus formation could result in fatal consequences such as ischemic heart
disease, myocardial infarction as well as stroke.
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1.4 The Endothelium
1.4.1

Endothelial Junctions
Endothelial cells form two major types of cell-cell adhesion complexes, adherens

junctions and tight junctions. In addition, endothelial cells have gap junctions that
mediate cell-cell communication. The adherens junctions and tight junctions exist
intermingled with each other at the boundaries of endothelial cells (Bazzoni and Dejana,
2004). The adherens junctions are thought to organize before the tight junctions and
regulate the assembly of tight junctions (Liebner et al., 2006). The junctional complexes
are in part responsible for maintaining vascular homeostasis. Endothelial cells are a
heterogeneous population and there are differences in the cell-cell junctions between
endothelial cells from different vascular beds. For example, the tight junctions in brain
endothelial cells are well developed and maintain strict control of permeability. The
venous endothelial cells on the other hand have poorly organized tight junctions to allow
dynamic movement of plasma proteins. The arterial endothelial cells have well developed
tight junctions and adherens junctions to maintain a semipermeable barrier. Accordingly,
it has been observed that HAEC and HUVEC show different permeability levels when
exposed to histamine (Ikeda et al., 1999). The authors showed that treatment of HAECs
with various concentrations of histamine showed no difference in permeability as
compared to untreated cells, whereas HUVECs showed a significant concentrationdependent increase in permeability. Under normal physiological conditions arterial
endothelial cells allow the passage of molecules smaller than 4 nm through the
intercellular junctions (Tedgui, 1996).
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1.4.2

Adherens Junction of Endothelial Cells
The molecular components of adherens junction includes the endothelial cell

specific vascular endothelial (VE)-cadherin and the catenins. VE-cadherin belongs to the
cadherin family of transmembrane glycoproteins. It consists of a cytoplasmic domain and
an extracellular region with five domains (EC1-EC5) (Fig. 5). VE-cadherin promotes
homotypic adhesion between cells via its extracellular domains in a calcium (Ca2+)
dependent manner. The EC1 domain of the extracellular region is proposed to participate
in the formation of cis/trans dimers and promote stable homophilic cell-cell adhesion
(Ivanov et al., 2001, Bazzoni and Dejana, 2004, Steinberg and McNutt, 1999). The
homophilic adhesion characteristics of cadherins were discovered when it was observed
that co-culture of cells expressing different types of cadherins results in aggregation of
cells with identical cadherins (Nose et al., 1988, Ivanov et al., 2001). The intercellular
adhesion mediated by VE-cadherin is Ca2+ sensitive. It has been observed that exposure
of HUVECs to 3 mM Ca2+ chelator, EGTA, causes the loss of VE-cadherin
immunostaining. Also, exposure of HUVECs to low Ca2+ (<10-7 M) in serum free
medium was observed to induce intercellular gaps that were reversible with the
introduction of medium containing serum and Ca2+ (Schnittler et al., 1997). VE-cadherin
along with other cadherins such as epithelial (E), neural (N), placental (P) and retinal (R)
belongs to the class of type I classical cadherins. The type II classical cadherins include
the recently discovered cadherins that are yet to be characterized (Ivanov et al., 2001).
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Fig. 5. The cadherin-catenin complex and actin cytoskeleton.
Reprinted, with permission, from the Annual Review of Cell and Developmental
Biology, Volume 13 ©1997 by Annual Reviews www.annualreviews.org

27

The cytoplasmic domain of VE-cadherin associates with β-catenin that in
turn is linked to the actin cytoskeleton via α-catenin (Ivanov et al., 2001) (Fig. 3). This
association is extremely important to maintain endothelial monolayer integrity. It has
been observed that mutant VE-cadherin with a truncated cytoplasmic domain, promotes
cell-cell adhesion via the extracellular domains but the association with β-catenin and
actin cytoskeleton is severely impaired (Navarro et al., 1995). As a result, the junctional
stability is compromised with increased endothelial permeability. The formation of a
stable cadherin-catenin complex has also been shown to be important for endothelial cell
survival as it activates phosphoinositide 3-kinase (PI3K) and Akt phosphorylation
(Carmeliet et al., 1999, Liebner et al., 2006). Other catenins such as γ-catenin (also
known as plakoglobin) and p120 catenin have been shown to associate with the adherens
junction complex. γ-Catenin has been shown to associate with the VE-cadherin in
HUVECs after formation of stable cell-cell adhesions and is proposed to strengthen the
adherens junction complex (Lampugnani et al., 1995, Schnittler et al., 1997). p120
catenin associates with the membrane proximal region of the cytoplasmic domain of VEcadherin and does not interact with any of the other catenins. Its role in cell-cell adhesion
has yet to be elucidated (Bazzoni and Dejana, 2004, Anastasiadis and Reynolds, 2000).
The tyrosine phosphorylation of adherens junction proteins plays a critical role in
the formation and maintenance of stable cell-cell adhesions. Tyrosine phosphorylation of
VE-cadherin and β-catenin is a normal physiological process. It has been observed using
HUVECs that loosely or recently confluent cells have increased tyrosine phosphorylation
of VE-cadherin and β-catenin (Lampugnani et al., 1997). The tyrosine phosphorylation
levels decrease when endothelial cells reach the fully confluent state. Furthermore, if the
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confluent endothelial monolayer is damaged, the cells at the migrating front show
increased tyrosine phosphorylation of VE-cadherin and β-catenin (Lampugnani et al.,
1997). The tyrosine phosphorylation of VE-cadherin and/or β-catenin can alter their
interaction with each other as well as the actin cytoskeleton. Association of adherens
junction proteins with the actin cytoskeleton is extremely important for maintaining the
mechanical strength and stability of the endothelial monolayer. The endogenous
mediator, histamine (10-4 M), has been shown to increase tyrosine phosphorylation of
both β-catenin and VE-cadherin in HUVECs or human dermal microvascular endothelial
cells (HMEC). This was accompanied by a decrease in the association of VE-cadherin
with the actin cytoskeleton as analyzed by the reduced distribution of VE-cadherin in the
detergent insoluble fraction (Andriopoulou et al., 1999). Intercellular gaps with increased
permeability were also observed with histamine treatment, implying that the VE-cadherin
mediated adhesion was compromised (Andriopoulou et al., 1999). Vascular endothelial
growth factor (VEGF) (50-100 ng/ml) has been shown to increase tyrosine
phosphorylation of VE-cadherin and β-catenin causing the loosening of adherens
junctions and increased permeability in HUVECs (Esser et al., 1998). The increase in
permeability due to disruption of the endothelial monolayer could accelerate
atherogenesis by increasing the transmigration of oxLDLs and monocytes into the intima
of blood vessels. Accordingly, it has been observed that injection of anti-VE-cadherin
blocking antibody into the tail vein of mice increased vascular permeability with damage
to the endothelial lining and deposition of monocytes and neutrophils in the areas of
exposed basement membrane (Corada et al., 1999). Similarly, another study documented
that intravenous injection of anti-VE-cadherin antibody increases vascular permeability
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and accelerates neutrophil entry into chemically inflamed mouse peritoneum (Gotsch et
al., 1997).
There are several protein tyrosine kinases such as Fyn, Fer, cMet, Abl and Src as
well as protein tyrosine phosphatases such as PTP1B, SHP1, SHP2 and VE-PTP that
have been shown to associate with and modulate the phosphorylation state of the
cadherin-catenin complex (Lilien and Balsamo, 2005, Yuan, 2003, Bogatcheva et al.,
2003, Xu et al., 2004, Daniel and Reynolds, 1997). The exact role of each of the tyrosine
kinases and phosphatases has yet to be elucidated, but each of these might act in an
unique temporal and spatial context to maintain stable cadherin-catenin mediated cell-cell
adhesion. It has been observed that the endothelial cell-specific protein tyrosine
phosphatase, VE-PTP, reduces the tyrosine phosphorylation of VE-cadherin induced by
VEGF and strengthens the cell-cell adhesion (Nawroth et al., 2002, Bazzoni and Dejana,
2004). Phosphorylation of β-catenin at tyrosine 654 by Src has been shown to cause a
fivefold reduction in its affinity for E-cadherin (Roura et al., 1999), which belongs to the
same class of type I classical cadherins as VE-cadherin (Ivanov et al., 2001). Therefore,
the phosphorylation/dephosphorylation states of the cadherin-catenin complex may be
modulated by complex interplay between tyrosine kinase and phosphatase activities.

1.5

Stress Fibers
Endothelial cells contain two pools of actin. Globular actin (G-actin) is the

monomeric form, which can undergo polymerization to form filamentous actin (F-actin)
(DuBose and Haugland, 1993, Oosawa, 2001). In nonmuscle cells such as endothelial
cells and fibroblasts, F-actin is involved in cell activities such as locomotion, cell
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adhesion, cytokinesis and maintenance of cell shape. Under normal physiological
conditions and in confluent endothelial cell culture, F-actin forms the dense peripheral
band (DPB) that is a thin layer of actin microfilaments near the plasma membrane (Wong
and Gotlieb, 1990, Guyton et al., 1989, Colangelo et al., 1998). F-actin also forms the
cytoplasmic stress fibers that extend from the cells periphery towards the central regions
or in some cases crossing the entire cell. Very few stress fibers may be visible in normal
endothelial cells, but can be dramatically increased in pathological conditions such as
hypertension and atherosclerosis (White et al., 1983, Guyton et al., 1989, Colangelo et
al., 1998). F-actin of the DPB is linked to the cadherin-catenin complex and plays a
critical role in maintaining endothelial monolayer integrity. Actin reorganization
associated with disruption of the endothelial barrier is characterized by increased stress
fiber density and reduction or loss of the DPB (Lum and Roebuck, 2001).
Stress fibers consist of several proteins such as myosin, tropomyosin and αactinin intermittently associated with the F-actin filaments (Byers et al., 1984). Stress
fibers are contractile elements. Stress fibers isolated from cultured human foreskin
fibroblast and bovine aortic endothelial cells have been shown to contract/shorten to
approximately 23% of the initial length (Katoh et al., 1998). Mitogenic stimulation of
3T3 fibroblast with 10% serum or 10 nM thrombin has been shown to induce contraction
of stress fibers accompanied by retraction of cell edges (Giuliano and Taylor, 1990).
The formation of stress fibers is regulated by the phosphorylation of myosin light
chain (MLC) of myosin II. Phosphorylation of MLC causes a conformational change in
the myosin molecule and promotes its association with actin, resulting in the assembly of
stress fibers (van Nieuw Amerongen and van Hinsbergh, 2001). The Ca2+/calmodulin-
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dependent myosin light chain kinase (MLCK) is considered to be the primary regulator of
MLC phosphorylation, since the Km of MLCK for MLC is 52 μM/L. The small GTPase,
Rho, has also been shown to modulate phosphorylation of MLC and development of
stress fibers by several mechanisms (van Nieuw Amerongen and van Hinsbergh, 2001).
Rho GTPase has been shown to phosphorylate MLC through Rho kinase. The Km of Rho
kinase for MLC is 0.91 μM/L. Rho GTPase has also been shown to inhibit the myosin
phosphatase type 1 (PP1M) responsible for dephosphorylation of MLC. In addition, Rho
GTPase has been proposed to induce stress fiber formation by induction of actin
polymerization and inhibition of actin depolymerization (van Nieuw Amerongen and van
Hinsbergh, 2001).
Disruption of endothelial monolayer integrity and increased endothelial
permeability have been associated with the development of stress fibers. It has been
shown that exposure of endothelial cells to apolipoprotein(a) component of
lipoprotein(a), a risk factor for atherosclerotic disorders, induces cytoplasmic stress fibers
with simultaneous loss of the DPB and VE-cadherin dispersion. This was accompanied
by cell retraction, intercellular gap formation and increased endothelial permeability in
HUVEC as well as HCAECs (Pellegrino et al., 2004). The formation of stress fibers was
shown to be dependent on increased phosphorylation of MLC by Rho GTPase and Rhokinase. Inhibition of Rho GTPase and Rho-kinase by pretreating HUVECs with C3
transferase and Y-27632, respectively, inhibited MLC phosphorylation, abolished the
formation of stress fibers and restored VE-cadherin at the cell-cell junctions. The
phosphorylation of MLC was also found to be Ca2+ dependent, although no increase in
intracellular Ca2+ was observed (Pellegrino et al., 2004). Other mediators of vascular
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permeability such as thrombin and histamine have also been shown to induce formation
of stress fibers. It has been observed that treatment of HUVECs with 1 μM α-thrombin or
histamine increases intracellular Ca2+ levels and formation of stress fibers with a
simultaneous increase in endothelial permeability (Ehringer et al., 1996, Ehringer et al.,
1999). Sandoval et al. (2001) further demonstrated that exposure of HUVECs to 10 nM
thrombin increases intracellular Ca2+ levels and MLC phosphorylation with a
concomitant increase in stress fibers. An increase in endothelial permeability was also
recorded. The authors suggest the involvement of Rho GTPase mediated signaling in the
observed effects.
The in vivo presence of stress fibers has been reported during hypertension and
atherosclerosis. It was observed that the aortic endothelium of spontaneously
hypertensive rats had more than a twofold higher proportion of endothelial cells
containing stress fibers than the age and sex-matched Wistar-Kyoto normotensive rats
(White et al., 1983). The stress fibers in the Wistar-Kyoto normotensive rats were also
thinner as compared to those in spontaneously hypertensive rats. The development of
stress fibers in atherosclerotic conditions was demonstrated using New Zealand white
rabbits. Guyton et al. (1989) demonstrated that 80% of the endothelial cells from control
aortas had either no stress fibers or were narrow, thin and no more than 1/3 the length of
the cell, if present. The same pattern of expression was also found in nonlesioned areas of
experimental cholesterol fed animals. The stress fibers in endothelial cells near and over
the atherosclerotic lesions were much more numerous than those observed in control
animals and extended the entire length of the endothelial cells. Furthermore, Colangelo et
al. (1998) characterized the stress fibers in early, minimal, intermediate and advanced
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lesions in rabbits fed with a high fat diet. The early lesions were characterized by
adhesion of leukocytes to the endothelium, minimal lesions consisted of few cells in the
subendothelium, intermediate lesions had numerous subendothelial leukocytes and the
advanced lesions consisted of several layers of leukocytes. The endothelial areas with
early lesions showed normal actin distribution as DPB. The minimal lesion areas showed
few cytoplasmic stress fibers whereas the intermediate lesion areas showed a decrease of
DPB and prominent cytoplasmic stress fibers. Isolated thick bundles of stress fibers were
also observed. Interestingly, the areas of advanced lesions showed no or few cytoplasmic
stress fibers (Colangelo et al., 1998). The authors suggested that the pattern of expression
of stress fibers signifies their involvement in the early stages of atherogenesis by
increasing endothelial permeability and transmigration of monocytes.

1.6

Protein Kinase C

1.6.1 Structure of Protein Kinase C
The protein kinase C (PKC) family members are serine/threonine kinases and
have been grouped into 3 classes based on their structural and enzymatic properties:
classical or conventional, novel and atypical PKC isotypes (Mellor and Parker, 1998,
Newton, 2001). The classical PKC (cPKC) includes α, the alternatively spliced β1 and β2,
and γ subtypes. The β1 and β2 isoforms differ at the C-terminal kinase domain; PKCβ1 has
50 residues and PKCβ2 has 52 residues (Kawakami et al., 2002). The novel PKC (nPKC)
consist of η, ε, δ and θ subtypes, and the ι and ζ subtypes belong to the atypical class of
PKC (aPKC). All members contain a regulatory region and a kinase domain that are
connected with each other by a proteolytically labile hinge region. The regulatory region
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consists of the pseudosubstrate site, and C1 and C2 domains. The kinase domain consists
of binding sites for ATP and substrate. The pseudosubstrate site of the regulatory region
interacts with the kinase domain and is responsible for suppression of PKC catalytic
activity. The C1 and C2 domains are the membrane-targeting modules. The C1 domain
binds diacylglycerol (DAG) and phosphatidyl serine (PS), and the C2 domain binds Ca2+.
The regulatory region of the cPKCs includes the C1 and C2 domains and requires Ca2+,
DAG and PS for activation. The nPKCs also consist of C1 and C2 domains in the
regulatory region but the C2 domain does not bind Ca2+ and therefore requires only DAG
and PS for activation. The aPKCs possess only the C1 domain and require only PS for
activation (Mellor and Parker, 1998, Newton, 2001).

1.6.2

Regulation of Classical Protein Kinase C isoforms
The activation and physiological function of cPKC isoforms is strictly regulated

by phosphorylation, binding of cofactors and subcellular localization (Newton, 2001).
Phosphorylation is the first step that primes newly synthesized cPKCs for catalytic
activity. cPKC isoforms are phosphorylated at one serine and two threonine residues in
the kinase domain. Phosphoinositide dependent kinase-1 (PDK-1) phosphorylates a
threonine residue (T497 in case of PKCα, T500 for PKC β1 and β2 and T514 for PKCγ),
following which the other threonine and serine residues are autophosphorylated. The
phosphorylation by PDK-1 is proposed to be constitutive, but dependent on a specific
conformation of cPKC (Newton, 2001, Sonnenburg et al., 2001, Newton, 2003). The
phosphorylated PKC molecule remains inactive in the cytosol until activated by cofactors
(Ca2+, DAG and PS). An increase in intracellular Ca2+ promotes its binding to
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phosphorylated PKC in the cytosol. Ca2+ binding triggers translocation of phosphorylated
PKC to the membrane and binding of DAG and PS for complete activation. Phorbol
esters that mimic DAG, are extremely potent activators of cPKCs and can cause
membrane translocation and activation without the need for PS or increased intracellular
Ca2+ (Newton, 2001). Apart from the cofactor based activation of cPKCs, their activity
has also been shown to be modulated by tyrosine phosphorylation (Konishi et al., 1997),
oxidative modification of the regulatory region (Gopalakrishna and Anderson, 1989), and
proteolysis at the hinge region (Kishimoto, et al., 1989).
The subcellular localization of the PKC isoforms plays a critical role in their
biological activity. Several proteins have been identified that interact with the different
PKC isoforms and position them in specific intracellular compartments or in close
proximity to the substrates, phosphatases or other kinases (Ron and Kazanietz, 1999). For
example, it has been observed that syndecan-4, a member of the transmembrane matrix
binding proteoglycans, associates with PMA activated PKCα and potentiates its activity.
This complex may colocalize to the focal adhesions (Oh et al., 1997). Another anchoring
protein, receptor for activated C kinase 1 (RACK1), has been shown to associate only
with activated PKCβ2 and regulate its intracellular localization (Newton, 2001, Ron and
Kazanietz, 1999). Interestingly, it was observed that the association of activated PKC
with RACK1 promotes the binding of RACK1 with Src tyrosine kinase (Chang et al.,
2001). Thus, RACK1 possibly mediates the cross talk between serine/threonine and
tyrosine kinase signaling pathways (Bauman and Scott, 2002, Chang et al., 2001). Further
identification and characterization of PKC binding proteins will aid in our understanding
of the complex regulation of PKC activities. Also, depending on cell types and
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experimental conditions, the activation and translocation of PKCs may differ. It was
observed that in response to different stimulating agents, PKCα translocation varies
within the same cell type and experimental conditions. Treatment of A7r5 smooth muscle
cells with 10-8 M phorbol 12, 13 dibutyrate, 10-5 M thapsigargin, 2 x 10-5 M A23187 or
10-6 M angiotensin II induced a varied spatial and temporal response in PKCα
translocation (Li et al., 2002). Furthermore, varying subcellular localization of the
different PKC isoforms (α, β1, β2, γ, δ, ε, ζ and η) was observed when NIH 3T3
fibroblasts were stimulated with 100 nM 12-O-tetradecanoylphorbol-13-acetate (TPA)
(Goodnight et al., 1995).

1.6.3

Classical Protein Kinase C and Regulation of the Endothelial barrier
Tyrosine phosphorylation of adherens junction proteins as well as development of

stress fibers could adversely affect the endothelial barrier. The cPKC isoforms, α and β,
have been implicated in the modulation of the endothelial barrier. It has been observed
that activation of PKCα by 50 nM α-thrombin activates Rho GTPase by dissociating it
from guanine dissociation inhibitor (GDI) in HUVECs (Mehta et al., 2001). The GDI
sequesters Rho in its GDP bound form and thereby prevents its activation (Rolfe et al.,
2005). Activated PKCα was also found to associate with Rho GTPase (Mehta et al.,
2001). Activation of Rho GTPase has been shown to induce stress fiber formation. Also,
activation of PKCα in HUVECs by 10 nM thrombin has been shown to cause MLC
phosphorylation with concomitant increase in stress fibers and endothelial permeability
(Sandoval et al., 2001). VEGF (100 ng/ml) has been shown to induce tyrosine
phosphorylation of β-catenin in a PKC dependent manner in bovine pulmonary artery
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endothelial cells, although the exact PKC isoform involved was not determined (Cohen et
al., 1999). Wang et al. (2004) further showed that 100 ng/ml VEGF mediates activation
of PKCβ1 and β2 isoforms in HUVECs and disrupts the association of VE-cadherin with
β-catenin. Inhibition of PKCα has been demonstrated to inhibit the ischemia-induced
endothelial permeability in porcine endothelial cells (Hempel et al., 1999). In vivo use of
PKCβ inhibitors in the treatment of vascular complications in diabetes mellitus has been
reported (Meier and King, 2000). Therefore, PKCs play a significant role in regulation of
the endothelial barrier.

1.7

Summary
Arsenic exposure has been associated with the development of CVD including

atherosclerosis. During the atherosclerotic process, the semipermeable property of the
endothelium is severely impaired. The endothelium is the most important barrier between
the blood and vessel wall, and adherens junction proteins play a significant role in the
maintenance of this barrier. The cadherin-catenin complex of the adherens junction
associates with the actin cytoskeleton that provides the strength and stability to the
endothelial barrier. The effects of arsenic on the proteins involved in maintaining
endothelial integrity remain unknown. Endogeneous mediators have implicated cPKCs in
the modulation of endothelial integrity. However, the effects of arsenic on PKC
activation vary with the experimental conditions. Arsenic has been shown to induce
peroxynitrite generation that can modulate signaling pathways. Controversial data exist
regarding the effects of peroxynitrite in activation of PKCs. Using human aortic
endothelial cells (HAECs), our laboratory tested the hypothesis that arsenic, via
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generation of peroxynitrite, induces the activation of cPKC (α and β) isotypes resulting in
the loss of endothelial monolayer integrity characterized by formation of actin stress
fibers, disruption of adherens junctions and increased endothelial permeability.
Epidemiological and animal studies have established the relationship between arsenic
exposure and atherosclerosis. But the time- and concentration-dependent effects of
arsenic in the development of atherosclerosis remain unknown. Therefore, we analyzed
the effects of low and environmentally relevant concentrations of arsenic on
atherogenesis using the ApoE-/- /LDLr-/- mouse model.
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Chapter 2
Time- and Concentration-Dependent Effects of Arsenic on
Atherogenesis in ApoE-/- /LDLr-/- Mice

2.1

Abstract
Exposure to arsenic through drinking water has been associated with

cardiovascular disease. In the present study, the effects of environmentally relevant
concentrations of arsenic in the development of atherosclerosis were investigated using
the well-established animal model of human atherosclerosis, mice deficient in
apolipoprotein E and low density lipoprotein receptor (ApoE-/- /LDLr-/-). The temporal
effects of arsenic were determined by exposing the mice to 10 ppm sodium arsenite
[As(III)] in drinking water for 5 or 10 weeks. Histology revealed that mice treated with
As(III) showed an increasing trend in atherosclerotic plaque formation within the
innominate arteries compared to the controls at both 5 and 10 weeks. Analysis of
interleukin-6 (IL-6) levels in the serum obtained from mice treated with As(III) for 10
weeks showed an increasing trend compared to the control mice. These results suggest
that As(III) contributes to atherogenesis at an early stage of the disease. The
concentration-dependent effects of arsenic were analyzed by exposing the ApoE-//LDLr-/- mice to 1, 5 and 10 ppm As(III) in drinking water for 20 weeks. A significant
increase in occlusion of the innominate arteries was observed with 1 and 5 ppm As(III).
An increasing trend in occlusion was observed with 10 ppm As(III), and serum IL-6
levels were significantly elevated in this group. These results demonstrate the
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significance of low levels of arsenic in both the onset and progression of atherosclerosis
in this animal model.

2.2

Introduction
Arsenic contamination of ground water is a global problem. In addition to the

United States, Taiwan, Bangladesh, India, China, Vietnam and Argentina have high
levels of arsenic in ground water ranging from 50-14,000 ppb (Wang and Wai, 2004).
Epidemiological evidence suggests that arsenic levels exceeding 20 ppb in drinking water
are associated with increased mortality from various cardiovascular diseases (Engel and
Smith, 1994). Atherosclerosis is the most important contributing factor to other
cardiovascular diseases and can lead to serious clinical manifestations such as ischemic
heart disease, myocardial infarction and stroke. Epidemiological studies have linked
arsenic exposure via drinking water to diseases such as carotid atherosclerosis (Wang et
al., 2002), ischemic heart disease (Tseng et al., 2003) and hypertension (Rahman et al.,
1999). Atherosclerosis is a multifactorial disease. The hallmark of atherosclerosis is
inflammation, characterized by the increased expression of cell adhesion molecules,
proinflammatory cytokines and chemokines (Tedgui and Mallat, 2006, Blankenberg et
al., 2003, Reape and Groot, 1999, Zeitler et al., 1997, Libby, 2002, Lusis, 2000). In
particular, increased levels of the proinflammatory cytokine, interleukin-6 (IL-6), have
been observed in patients with acute myocardial infarction (Erren et al., 1999, Ikeda et
al., 1992), and it has been implicated in smooth muscle cell proliferation, formation of
atherosclerotic lesions and instability of the atherosclerotic plaques (Ikeda, 2003, Rattazzi
et al., 2003). Also, elevated levels of soluble vascular cell adhesion molecule-1 (sVCAM-

60

1) have been observed in patients with coronary heart disease and myocardial infarction
(Zeitler et al., 1997), although its pathological role is unclear.
In addition to the epidemiological evidence, controlled animal studies have
confirmed the association between arsenic exposure and development of atherosclerosis.
It has been shown that exposure to 20 and 100 ppm arsenic in drinking water for 24
weeks accelerates atherogenesis in apolipoprotein E knockout (ApoE-/-) mice
(Simeonova et al., 2003). Furthermore, we showed that chronic exposure (18 weeks) to
10 ppm arsenic in drinking water exacerbates atherosclerotic plaque formation in
apolipoprotein E and low density lipoprotein receptor double knockout (ApoE-/- /LDLr-/) mice (Bunderson et al., 2004). The ApoE-/- /LDLr-/- mouse is a well established model
of human atherosclerosis. Mice are resistant to the development of atherosclerosis, but
targeted gene deletion of ApoE and LDLr in mice results in hyperlipidemia and
atherosclerosis that resembles human disease (Ishibashi et al., 1994, Jawein et al., 2004).
While, the animal studies have helped to clearly establish the link between arsenic
exposure and atherosclerosis by eliminating the confounding factors that obscure
epidemiological studies, the temporal effects of arsenic exposure in the development of
atherosclerosis have not been identified. Also, the effects of arsenic concentrations lower
than 10 ppm on atherogenesis have yet to be determined. In the present study, we
investigated the time- and concentration-dependent effects of arsenic on the development
of atherosclerosis in the ApoE-/- /LDLr-/- mouse.
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2.3

Materials and Methods

2.3.1

Experimental animals. ApoE-/- /LDLr-/- mice were obtained from Jackson

Laboratories (Bar Harbor, ME). All the animals were housed under specific pathogenfree conditions according to IACUC protocols with 12 h light/dark cycle and controlled
temperature. The animals receiving arsenic treatment were given either 10 ppm As(III)
(GFS Chemicals, Columbus, OH) for 5 or 10 weeks or 1, 5 and 10 ppm As(III) for 20
weeks ad libitum via drinking water. The control group received ddH2O. The mice were
fed a commercial mouse chow diet. Male and female animals were evenly distributed
between treatment and control groups and were 4-7 weeks of age at the beginning of the
study. Mice were weighed at the beginning and termination of the study.

2.3.2

Dissection procedures and quantification of atherosclerotic plaques. At the

termination of treatments, blood was collected from each animal and the mice were
perfused with 1% paraformaldehyde/PBS. The dissection of the innominate artery and
quantification of the atherosclerotic plaques were done as described by Bunderson et al.
(2004) with slight modifications. Briefly, cross sections of 10 μm thickness were
obtained from paraffin-embedded innominate arteries of control and As(III)-treated mice.
To ensure that the majority of plaque expanse was analyzed, the fifth, tenth and fifteenth
sections of each sample, beginning from the base of the innominate artery, were stained
with Movat’s pentachrome. The sections were examined using blinded methods. Image
analysis was done using NIH ImageJ software.
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2.3.3

Enzyme-linked immunosorbent assay. Blood collected from ApoE-/- /LDLr-/-

mice treated with 10 ppm As(III) for 10 or 20 weeks was used to analyze serum IL-6 and
sVCAM-1 levels. Serum was obtained by centrifugation of the blood at 1,600 rpm for 5
min at 4 0C and was stored at -80 0C until analysis. Serum IL-6 and sVCAM-1 levels
were analyzed by ELISA kits from BD Biosciences (San Diego, CA) and R&D Systems
(Minneapolis, MN), respectively, according to the manufacturer’s instructions.

2.3.4

Statistical analysis. Results are presented as mean ± standard error of the mean

(SEM). Statistical analysis was performed using Student’s t test when comparing two
groups or Bonferroni method for comparing three groups or more. When using the
Bonferroni method, the alpha level of each individual test was adjusted downwards to
ensure that the overall experiment wise-risk remains at 0.05. Statistical analysis was
performed using GraphPad Prism, version 4.00. Alpha error was set at p<0.05.

2.4

Results and Discussion
Epidemiological studies have associated arsenic exposure with the development

of cardiovascular diseases such as carotid atherosclerosis and ischemic heart disease
(Wang et al., 2002, Tseng et al., 2003). Previous studies, using animal models of
atherosclerosis, have shown that exposure of mice to 10, 20 and 100 ppm arsenic
exacerbates the process of atherosclerosis (Bunderson et al., 2004, Simeonova et al.,
2003). This is the first study to show that low and environmentally relevant
concentrations of arsenic (1 and 5 ppm) significantly increase atherosclerotic plaque
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formation in the ApoE-/- /LDLr-/- mice. Analysis of the temporal effects of arsenic
suggests that it may also contribute to the initiation of atherosclerosis.
The concentration-dependent effects of As(III) in the development of
atherosclerosis were determined by exposing ApoE-/- /LDLr-/- mice to 1, 5 and 10 ppm
As(III) in drinking water for 20 weeks (Fig. 6). Atherosclerotic plaque development was
determined by measuring the percent occlusion of the innominate artery, which is a small
vessel that connects the aortic arch to the right subclavian and right carotid arteries.
Development of atherosclerotic lesions in this artery has been shown to progress at a
highly consistent rate and closely resemble that of human condition, with events such as
intraplaque hemorrhage and loss of fibrous cap or plaque rupture (Rosenfeld et al., 2000).
The innominate arteries obtained from mice exposed to 1, 5 and 10 ppm As(III) were
stained with Movat’s pentachrome (Fig. 6A). The percent occlusion of the innominate
artery was determined by dividing the plaque area by the lumen area plus the plaque area.
Histology revealed a significant increase in plaque formation with 1 and 5 ppm As(III)
treatment compared to the control group (Fig. 6B).
These concentrations of arsenic are well within the range encountered in the water
supplies of the aforementioned countries having 0.05-14 ppm of arsenic contamination in
drinking water (Wang and Wai, 2004). This finding is remarkable when considering that
the toxicity of arsenic in humans could be much greater than that in mice at equivalent
concentrations. Mice excrete approximately 90% of ingested arsenic in 2 days, whereas
the biological half-time of arsenic in humans is on the order of 4 days (Vahter, 2000).
Therefore, human subjects could be even more susceptible to arsenic-induced
cardiovascular toxicity.
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Our lab has previously shown that exposure to 10 ppm As(III) for 18 weeks
significantly increases atherosclerotic plaque formation in ApoE-/- /LDLr-/- mice
(Bunderson et al., 2004). In the present study, however, only an increasing trend in
plaque formation was observed with 10 ppm As(III) treatment for 20 weeks (Fig. 6B)
along with a significant increase in IL-6 levels (Fig. 8B). Increases in IL-6 levels have
been strongly correlated with atherosclerotic plaque instability and rupture in human
subjects (Schieffer et al., 2000) as well as a mouse model (Cheng et al., 2006). IL-6 is an
important factor for increased plaque vulnerability because it stimulates the matrix
degrading enzymes such as metalloproteinases (Cheng et al., 2006, Schieffer et al., 2000,
Lin et al., 2007). In addition, studies have demonstrated the expression of IL-6 in the
lipid-rich shoulder areas of plaques that are the most vulnerable sites of plaque rupture
(van der Wal et al., 1994, Schieffer et al., 2000, Cheng et al., 2006). Therefore, it is
possible that plaque rupture might have contributed to the statistically non-significant
increase in atherosclerotic plaques observed with 10 ppm As(III) treatment for 20 weeks
compared to our previous finding at 18 weeks of As(III) treatment (Bunderson et al.,
2004). To ensure that the mice were sufficiently hydrated and healthy, all the animals
were weighed at the beginning (initial weight) and at the termination (final weight) of the
study. Final and initial weights were not significantly different between the control group
and the As(III) treated groups (Table 1). In addition, visual inspection of the animals
revealed no apparent adverse effects related to As(III) treatment on the general health of
the animals.
The temporal effects of As(III) on atherogenesis were determined by exposing the
ApoE-/- /LDLr-/- mice to 10 ppm As(III) via drinking water for 5 or 10 weeks (Fig. 7).
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The innominate arteries obtained from mice exposed to As(III) for 5 weeks (Fig. 7A) and
10 weeks (Fig. 7C) were stained with Movat’s pentachrome. Histology revealed an
increasing trend in plaque formation with As(III) treatment at 5 weeks (Fig. 7B) and 10
weeks (Fig. 7D) compared to the control mice. These results suggests that As(III) may
affect the initiation of atherosclerosis since an increasing trend in plaque formation was
observed as early as 5 weeks. An initiating event in the development of atherosclerosis is
increased accumulation of oxidized low density lipoproteins (LDLs) and monocytes
within the blood vessel intima that leads to the formation of foam cells and ultimately
culminates with the development of plaques (Lusis, 2000, Libby, 2002). Damage to the
endothelium can result in increased permeability/passage of oxidized LDLs and
monocytes across the endothelial monolayer. Consistent with this, we have recently
documented that arsenic treatment induces intercellular gaps and increases permeability
in cultured human aortic endothelial cells (Pereira et al., 2007), and in situ arsenic
treatment has been shown to increase vascular permeability in rodents (Chen et al., 2004,
Tsai et al., 2005). In addition, IL-6 has been shown to increase endothelial permeability
(Desai et al., 2002). We observed that with 10 ppm As(III) treatment, serum IL-6 levels
showed an increasing trend at 10 weeks (Fig. 8A) and a significant increase at the 20
week time point (Fig. 8B). Therefore, arsenic could potentially affect the initiation of
atherosclerosis by increasing vascular permeability and the accumulation of oxidized
LDLs and monocytes within the neo-intima of the blood vessel.
Surprisingly, a significant decrease was observed in sVCAM-1 levels at both 10
week (Fig. 9A) and 20 week (Fig. 9B) time points with 10 ppm As(III) treatment. The
expression of VCAM-1 by endothelial cells is an early event in the development of
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atherosclerosis (Nakashima et al., 1998). The role of VCAM-1 expressed by endothelial
cells in atherogenesis is well characterized and is known to mediate transmigration of
monocytes into the blood vessel intima (Cybulsky et al., 2001, Nakashima et al., 1998,
Lusis, 2000). The soluble form of VCAM-1 has been proposed to be a prognostic factor
in clinical manifestations such as myocardial infarction, coronary artery disease and
unstable angina. However, contradictory results have been documented regarding the
correlation of sVCAM-1 with cardiovascular events. Rohde et al. (1998) and Zeitler et al.
(1997) demonstrated a correlation between increased serum levels of sVCAM-1 with
carotid atherosclerosis and myocardial infarction, whereas Hwang et al. (1997) and Saku
et al. (1999) found no such correlation. Furthermore, the clinical relevance of the
sVCAM-1 is unclear (Blakenberg et al., 2003, Lind, 2003). The genesis of soluble form
of VCAM-1 is also not certain. The most widely accepted theory is the proteolytic
cleavage of cell surface expressed VCAM-1 molecule by an unidentified metalloprotease
(Leca et al., 1995) and the relation between cellular expression and amount of soluble
forms has yet to be elucidated (Blakenberg et al., 2003). This study does not suggest that
there is reduced expression of endothelial VCAM-1. One possible interpretation for the
reduced sVCAM-1 is that the increased interaction of the leukocytes with endothelial
VCAM-1 may inhibit the proteolytic cleavage. Another possibility is increased clearance
of these plasma proteins, although the mechanism of clearance or catabolism remains
unknown. As mentioned above, it might also be possible that arsenic exacerbates the
process of atherosclerosis by damaging the endothelial monolayer and not by modulating
all of the classical mediators.
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Atherosclerosis is a multifactorial disease with complex interplay between various
signaling pathways and inflammatory mediators. Arsenic is a versatile molecule, and
several mechanisms have been proposed by which it might modulate vascular
homeostasis and influence the development of atherosclerosis (reviewed in Navas-Acien
et al., 2005). Therefore, it is possible that arsenic affects atherogenesis by triggering
multiple mediators. In summary, this study showed that environmentally relevant
concentrations of arsenic induce significant increases in atherosclerotic plaque formation
in the ApoE-/- /LDLr-/- mouse. Furthermore, the process of atherosclerosis is plausibly
initiated or accelerated by arsenic at an early stage. Additional mechanistic studies are
needed to elucidate how arsenic contributes to the onset and progression of
atherosclerosis.
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2.5

Figures

Fig. 6. Concentration-dependent effect of As(III) in the development of
atherosclerosis
A.
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B.

Fig. 6. Concentration-dependent effect of As(III) in the development of atherosclerosis.
ApoE-/- /LDLr-/- mice were given either ddH2O (control) or 1, 5 and 10 ppm As(III) in
drinking water for 20 weeks and the concentration-dependent effects of As(III) in the
development of atherosclerotic plaque within the innominate arteries were analyzed (A);
magnification=10X. Percent occlusion of the innominate arteries was analyzed (B) with
n=10-19 mice per group and the treatment groups marked with asterisk were significantly
different from the control (*, p<0.01).
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Fig. 7. Temporal effect of As(III) in the development of atherosclerosis
A.

B.
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C.

D.

Fig. 7. Temporal effect of As(III) in the development of atherosclerosis. ApoE-/- /LDLr/- mice were given either ddH2O (control) or 10 ppm As(III) in drinking water and the
temporal effects of As(III) in the development of atherosclerotic plaques within the
innominate arteries were analyzed at 5 week (A) or 10 week (C) time points;
magnification=10X. Percent occlusion of the innominate arteries was analyzed at 5 weeks
(B) with 11-14 mice per group and 10 weeks (D) with 7-12 mice per group.
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Fig. 8. Effect of As(III) treatment on serum IL-6 levels
A.

B.

Fig. 8. Effect of As(III) treatment on serum IL-6 levels. IL-6 levels were measured by
ELISA in the serum of ApoE-/- /LDLr-/- mice given either ddH2O (control) or 10 ppm
As(III) for (A) 10 weeks or (B) 20 weeks (n=6-7 mice per group). Treatment group
marked with asterisk was significantly different from the respective control (*, p<0.05).
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Fig. 9. Effect of As(III) treatment on serum levels of sVCAM-1

A.

B.

Fig. 9. Effect of As(III) treatment on serum levels of sVCAM-1. sVCAM-1 levels were
measured by ELISA in the serum of ApoE-/- /LDLr-/- mice given either ddH2O (control)
or 10 ppm As(III) for (A) 10 weeks or (B) 20 weeks (n=7 mice per group). Treatment
group marked with asterisk were significantly different from the respective control (*,
p<0.05).
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Table 1. Body weight of mice exposed to As(III) for 20 weeks.
Initial weight (g)

Final weight (g)

Difference (g)

Control

17.59 ± 0.44

19.93 ± 0.43

2.35 ± 0.27

1 ppm As(III)

19.54 ± 0.35

21.3 ± 0.37

1.76 ± 0.18

5 ppm As(III)

17.61 ± 0.59

20.08 ± 0.56

2.47 ± 0.16

10 ppm As(III)

20.91 ± 0.60

23.04 ± 0.63

2.14 ± 0.20

Each value represents mean ± SEM; no significant differences observed between groups.
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Chapter 3
Activation of Protein Kinase C and Disruption of Endothelial
Monolayer Integrity by Sodium Arsenite

3.1

Abstract
The endothelium maintains a semipermeable barrier between the blood and vessel

wall. The objective of the present study was to determine whether arsenic treatment
induces activation of protein kinase C (PKC) isoforms, α and β, by generation of the
reactive nitrogen species, peroxynitrite, and thereby causes endothelial disruption.
Human aortic endothelial cells (HAECs) were exposed to 1, 5 and 10 μM sodium arsenite
[As(III)] for 1, 6, 12 and 24 h. Western blotting revealed that As(III) treatment induced a
concentration-dependent increase in activation of PKCα with no change in PKCβ levels.
The activation of PKCα was found to be calcium-dependent. Peroxynitrite formation was
not observed with As(III) treatment. Endothelial barrier integrity is maintained by
proteins of the adherens junction, vascular endothelial (VE)-cadherin and β-catenin, and
their association with the actin cytoskeleton. Immunofluorescence studies revealed
reorganization of actin filaments into stress fibers and non-uniform staining of VEcadherin and β-catenin at cell-cell junctions that were concentration- and time-dependent.
Intercellular gaps were observed with a measured increase in endothelial permeability. In
addition, a concentration-dependent increase in tyrosine phosphorylation of β-catenin was
detected by Western blotting. Inhibition of PKCα using the classical PKC inhibitor, Gö
6979, restored VE-cadherin and β-catenin staining at cell-cell junctions and abolished the
As(III) induced formation of intercellular gaps and actin stress fibers. Endothelial
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permeability and tyrosine phosphorylation of β-catenin were also reduced to basal levels.
These results suggest that As(III) induces activation of PKCα, which leads to increased
tyrosine phosphorylation of β-catenin and formation of actin stress fibers downstream of
PKCα activation. Phosphorylation of β-catenin plausibly severs the association of VEcadherin and β-catenin, which along with formation of actin stress fibers, results in
intercellular gap formation and increased endothelial permeability. As(III)-induced loss
of endothelial monolayer integrity may contribute to the development of atherosclerosis
by accelerating the accumulation of oxidized low density lipoproteins and monocytes
within the blood vessel intima.

3.2

Introduction
Arsenic, an element present in the earth’s crust, has been widely distributed in the

environment by human activities such as mining, smelting, pesticide application and
manufacturing and use of products such as wood preservatives and dyes. Epidemiological
studies analyzing the correlation between cardiovascular diseases and arsenic exposure
have linked arsenic to atherosclerosis (Wang et al., 2002), ischemic heart disease (Tseng
et al., 2003) and hypertension (Rahman et al., 1999). Drinking water is a significant
source of arsenic exposure to humans. Using mouse models of atherosclerosis, we and
others have demonstrated that chronic exposure to arsenic through drinking water
exacerbates atherosclerotic plaque formation (Bunderson et al., 2004, Simeonova et al.,
2003). Atherosclerosis can lead to serious clinical manifestations such as heart attack and
stroke.
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Arsenic has been shown to generate reactive oxygen species such as superoxide
anion and hydrogen peroxide (Barchowsky et al., 1999a) in porcine aortic endothelial
cells and reactive nitrogen species such as nitric oxide and peroxynitrite in bovine aortic
endothelial cells (Bunderson et al., 2002, Lynn et al., 1998, Liu and Jan, 2000).
Peroxynitrite is a strong oxidizing and nitrating molecule formed by the rapid reaction of
superoxide with nitric oxide. Peroxynitrite has been reported to interfere with cellular
processes and signal transduction pathways by oxidation as well as nitration of proteins
(Klotz et al., 2002). Amino acids such as cysteine, tyrosine, methionine and tryptophan
are known to be modified by peroxynitrite via oxidation or nitration (Pryor and
Squadrito, 1995, Radi et al., 2001, Beckman, 1996). In particular, 3-nitrotyrosine is a
stable product that is formed by the attack of peroxynitrite on protein tyrosine residues.
The detection of 3-nitrotyrosine in biological samples has been used as a marker for the
presence of peroxynitrite (Ischiropoulos, 1998, Beckman et al., 1994, Beckman and
Koppenol, 1996, Beckman, 1996).
There are numerous regulatory points in the vascular system that may be
disrupted and lead to atherogenesis. The integrity of the vascular endothelium is
maintained by proteins of the adherens junctions that includes the transmembrane protein
vascular endothelial (VE)-cadherin linked to the cytoplasmic protein β-catenin, which in
turn is linked to the actin cytoskeleton through α-catenin (Ivanov et al., 2001). This
association is critical to maintaining cell-cell adhesion and structural integrity. The
tyrosine phosphorylation of adherens junction proteins can alter their interaction with
each other and the cytoskeleton. Endogenous mediators such as histamine have been
shown to increase tyrosine phosphorylation of both β-catenin and VE-cadherin, resulting
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in dissociation of VE-cadherin from the actin cytoskeleton with a subsequent increase in
vascular permeability (Andriopoulou et al., 1999). The tyrosine phosphorylation of βcatenin has been shown to cause a fivefold reduction in its affinity for E-cadherin (Lilien
and Balsamo, 2005, Roura et al., 1999). Accordingly, vascular endothelial growth factor
(VEGF) induced tyrosine phosphorylation of VE-cadherin and β-catenin has been
implicated in the loosening of cell-cell contacts and increased vascular permeability
(Esser et al., 1998).
The association of cadherin-catenin complex with the actin cytoskeleton is also
very important for maintaining junctional stability. Reorganization of the actin filaments
into stress fibers can compromise the stability of the endothelial monolayer. Stress fibers
consist of proteins such as myosin, tropomyosin and α-actinin intermittently associated
with the actin filaments (Byers et al., 1984). Stress fibers are contractile elements and
have been shown to develop in vivo during endothelial cell adaptation to unfavorable or
pathological situations such as atherosclerosis and hypertension (White et al., 1983,
Guyton et al., 1989, Colangelo et al., 1998). It has been observed that the
apolipoprotein(a) component of lipoprotein(a), a risk factor for atherosclerotic disorders,
induces stress fiber formation and VE-cadherin dispersion accompanied by cell
retraction, intercellular gap formation and increased endothelial permeability (Pellegrino
et al., 2004). Thus, development of stress fibers in endothelial cells adversely affects
monolayer integrity. Treatment with peroxynitrite or the peroxynitrite donor, 3morpholinosydnonimine hydrochloride (SIN-1), has been shown to induce actin stress
fibers and nitration of tyrosine residues on actin and β-catenin in porcine aortic
endothelial cells with an increase in permeability (Knepler et al., 2001). Nitration of these
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proteins was proposed to be the cause of endothelial disruption. However, the effects of
arsenic on the proteins involved in maintaining endothelial monolayer integrity remain
unknown.
Several signaling intermediates have been implicated in the regulation of
endothelial barrier function. In particular, the various protein kinase C (PKC) isotypes
have a host of cellular substrates and are involved in numerous biological processes.
PKCs are serine/threonine kinases and have been grouped into 3 subfamilies: classical,
novel and atypical PKCs (Newton, 2001). The classical PKCs (cPKC), which consists of
α, β and γ subtypes, are activated in calcium (Ca2+)-dependent manner and require
diacylglycerol and phosphatidylserine. The PKCβ gene is alternatively spliced into
PKCβ1 and β2 isoforms that differ by 2 amino acids in the C-terminal kinase domain. The
PKCβ1 isoform consists of 50 residues and the β2 isoform has 52 residues (Kawakami et
al., 2002). Among the cPKCs, endothelial cells express α and β isotypes (Mattila et al.,
1994). The cPKCs have been implicated in the modulation of endothelial barrier function
(Yuan, 2003). Activation of PKCα by thrombin has been shown to induce actin stress
fibers and increase endothelial permeability (Sandoval et al., 2001). VEGF has been
shown to activate PKCα, PKCβ1 and β2, and inhibition of the PKCβ isoforms was
demonstrated to inhibit the dissociation of β-catenin from VE-cadherin and reduce
endothelial permeability observed with PKC activation (Wang et al., 2004). Nagpala et
al. (1996) have demonstrated that overexpression of PKCβ1 in endothelial cells increases
permeability when stimulated with phorbol ester. Conflicting data exist regarding the
effects of arsenic on the modulation of intracellular Ca2+ levels and cPKCs; effects that
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are dependent on the cell line studied and the duration of arsenic treatment (Chen et al.,
2000, Liu and Huang, 1997).
Peroxynitrite has been implicated in the modulation of cPKC activity. It has been
shown that treatment of endothelial cells with peroxynitrite results in an increase in Ca2+dependent PKCα activity that was inhibited by the intracellular Ca2+ chelator, BAPTAAM, and the cPKC inhibitor, Gö 6976. Peroxynitrite treatment also induced tyrosine
nitration of PKCα (Chakraborti et al., 2005). Conversely, peroxynitrite treatment has
been shown to nitrate tyrosine residues and inactivate PKCα and β isoforms in
hippocampal homogenates and rat brain purified PKC (Knapp et al., 2001). The effect of
arsenic-induced peroxynitrite formation in the modulation of cPKC activation remains
unknown.
Various mechanisms for arsenic-induced atherosclerosis have been proposed
including activation of the endothelium that is characterized by up-regulation of adhesion
molecules and inflammatory mediators (Simeonova and Luster, 2004). In particular, in
situ arsenic exposure through intradermal injections on the dorsal surface of rats has been
shown to induce vascular permeability (Chen et al., 2004). However, the mechanism of
increased vascular permeability remains unknown. The endothelium maintains a
semipermeable barrier and damage to the endothelial lining can result in increased
permeability. This could lead to subsequent recruitment and migration of monocytes and
oxidized low density lipoproteins (oxLDL) into the intima of the blood vessel, thereby
promoting the development of atherosclerotic lesions. Hence, the objective of this study
was to determine the effects of arsenic on endothelial barrier integrity and characterize
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the pathways for arsenic-induced increases in vascular permeability. We also analyzed
whether the effects of arsenic were mediated through formation of peroxynitrite.

3.3

Materials and Methods

3.3.1

Cell culture. Human aortic endothelial cells (HAECs) were purchased from

Cambrex Bio Science (Walkersville, MD) and were grown in the supplier’s formulated
medium:

EBM-2

medium

supplemented

with

EGM-2

SingleQuots

(0.04%

hydrocortisone, 0.4% hFGF-B, 2% FBS and 0.1% each of VEGF, R3-IGF-1, ascorbic
acid, heparin, hEGF and GA-1000). Bovine aortic endothelial cells (BAECs) were
provided by Dr. J. Douglas Coffin of The University of Montana, Missoula and were
originally a gift from Dr. Steve Schwartz of The University of Washington. Cells were
grown in Dulbecco’s Modified Eagle Medium (DMEM) with penicillin/streptomycin and
L-glutamine, and supplemented with 15% FBS (Mediatech, Inc., Herndon, VA). The
HAECs and BAECs were incubated at 37 0C under a humidified atmosphere containing
5% CO2. Cells were used between passages 2 and 10.

3.3.2

Cell viability assay. The viability of HAECs was determined using the 3-(4,5-

dimethythiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay described by
Bunderson et al. (2002) with some modifications. HAECs were seeded at a density of
1x104 cells/well in 96-well plates. At 24 h post seeding, cells were treated with 0.5, 1,
2.5, 5, 10, 25, 50, 100, 250 or 500 μM concentrations of sodium arsenite [As(III)] (GFS
Chemicals, Columbus, OH) for 12, 24 and 48 h. The treatment solutions were removed
and replaced with medium alone for 24 h. MTT/medium solution (50 μg) was added to
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each well and cells were incubated for another 4 h. The MTT/medium solution was
carefully removed and the formazan crystals were dissolved in 100 μl DMSO/well.
Absorbance was determined using the VersaMax microplate reader (Molecular Devices
Corporation, Sunnyvale, CA) at 560 nm. The effect of Gö 6976 (Calbiochem, San Diego,
CA), nitro-L-arginine methyl ester (L-NAME) (Sigma-Aldrich, Saint Louis, MO) and
5,10,15,20-Tetrakis-[4-sulfonatophenyl]-porphyrinato-iron[III],

Chloride

(FeTPPS)

(Calbiochem, San Diego, CA) on cell viability for 24 h was also determined.

3.3.3

Detection of Peroxynitrite. Generation of peroxynitrite with As(III) treatment

was determined in HAECs and BAECs by analyzing nitrotyrosine formation. Cells were
grown on 18-mm round coverslips inserted into 12-well plates. For HAECs 0.1 mg/ml
solution of Poly-D-Lysine hydrobromide (Sigma-Aldrich, Saint Louis, MO) was used to
coat the coverslips. HAECs and BAECs were seeded at a density of 2x105-3x105
cells/well in 12-well plates and were grown to confluence for 48-72 h. Cells were then
treated with As(III) for specified time periods. Cells were fixed with 1%
paraformaldehyde/phosphate-buffered saline (PBS) for 30 min at room temperature (RT),
permeabilized using 0.1% saponin solution/ PBS for 10 min at RT and then blocked with
5% goat serum/PBS (Sigma-Aldrich, Saint Louis, MO) for 30 min at RT. Cells were then
incubated with 20 μg/ml rabbit anti-nitrotyrosine polyclonal antibody for 24 h at 4 0C
followed by incubation with 10 μg/ml Alexa Fluor 594-conjugated goat anti-rabbit
secondary antibody (Molecular Probes, Inc. Eugene, OR) for 1 h at RT in the dark. Cells
were counterstained with Hoechst 33342 stain for 5 min at RT, coverslipped with
Fluorosave (EMD Biosciences, San Diego, CA) and stored in the dark until imaged.
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Fluorescence was quantitated using a Laser Scanning Cytometer (CompuCyte
Corporation, Cambridge, MA).
Generation of peroxynitrite with As(III) treatment was also determined in HAECs
by analyzing the oxidation of hydroethidine to its fluorescent form ethidium (Zhao et al.,
2005, Zhao et al., 2003). HAECs were grown in 24-well plates coated with 0.1 mg/ml
solution of Poly-D-Lysine hydrobromide. Cells were seeded at a density of 1x105
cells/well and grown to confluence for 48-72 h. Cells were incubated with 20 μM
hydroethidine/PBS for 30 min at 37 0C. PBS was supplemented with 1 mM CaCl2, 0.5
mM MgCl2 and 2% fetal bovine serum and was used for rinsing cells and preparing all
the solutions for this experiment. Cells were rinsed twice with PBS and then incubated
with As(III)/PBS with or without the peroxynitrite decomposition catalyst, FeTPPS, for 1
h at 37 0C. The total volume of solution in each well was 1 ml at all times except during
fluorescence measurement when the volume was reduced to 200 μl. Fluorescence
intensity was analyzed using the SpectraMax GeminiXS fluorescence plate reader
(Molecular Devices Corporation, Sunnyvale, CA) at 510 nm excitation and 590 nm
emission wavelengths (Zhao et al., 2005, Zhao et al., 2003).

3.3.4

Immunofluorescence. HAECs were grown on 18-mm round coverslips inserted

into 12-well plates and coated with 0.1 mg/ml solution of Poly-D-Lysine hydrobromide.
HAECs were seeded at a density of 2x105-3x105 cells/well and were grown to confluence
for 48-72 h. Cells were treated with As(III) and the cPKC inhibitor, Gö 6976, was added
1 h prior to and during the As(III) treatment wherever applicable. Cells were fixed with
1% paraformaldehyde/PBS for 30 min at RT, permeabilized using 0.1% saponin/PBS for
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10 min at RT and then blocked with 5% goat serum/PBS for 30 min at RT. Cells were
then incubated with either 2 μg/ml rabbit anti-VE-cadherin polyclonal antibody (Cayman
Chemicals, Ann Arbor, MI) or 2 μg/ml rabbit anti-β-catenin polyclonal antibody
(Cayman Chemicals, Ann Arbor, MI) or 0.24 μg/ml rabbit polyclonal antibody against
cleaved caspase-3 (Cell Signaling Technology, Danvers, MA) in PBS for 2 h at RT or 24
h at 4 0C followed by incubation with 10 μg/ml Alexa Fluor 488-conjugated goat antirabbit secondary antibody (Molecular Probes, Inc. Eugene, OR) for 1 h at RT in the dark.
For detection of stress fibers, HAECs were incubated with 16.5 nM Alexa Fluor 568conjugated phalloidin (Molecular Probes, Inc. Eugene, OR) for 25 min at RT in the dark.
Cells were counterstained with Hoechst 33342 stain for 5 min at RT, coverslipped with
Fluorosave and stored in the dark until imaged. Slides were photographed with a Nikon
Digital Eclipse DXM1200 camera attached to a Nikon E-800 microscope using a 60X oil
immersion lens.

3.3.5

Permeability Assay. HAECs (1x105-1.5x105) were seeded on 0.4-μm pore

polyester membrane transwell inserts (Corning Incorporated, Acton, MA) coated with 0.1
mg/ml solution of Poly-D-Lysine hydrobromide in 12-well plates. Cells were grown to
confluence for 48-72 h. The volume of medium in the Transwell was 500 μl with 1.5 ml
in the plate well at all times. The As(III) treatments were added to the Transwells and the
cPKC inhibitor, Gö 6976, was added 1 h prior to and during the As(III) treatment
wherever applicable. At the final 1 h of respective treatments, fluorescein isothiocyanate
(FITC)-labeled dextran (average molecular weight 40,000, final concentration of 1
mg/ml; Sigma-Aldrich, Saint Louis, MO) was added to each Transwell including control
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wells. After completion of the treatment period, the fluorescence intensity of the medium
in the plate well was analyzed using a SpectraMax GeminiXS fluorescence plate reader.
For each sample, 5 aliquots of 200 μl each were analyzed using an excitation wavelength
of 490 nm and emission wavelength of 520 nm.

3.3.6

Immunoprecipitation of VE-cadherin and β-catenin. To detect tyrosine

phosphorylation and tyrosine nitration of VE-cadherin and β-catenin, the proteins were
first immunoprecipitated. HAECs were seeded at a density of 7.5x105 cells/25 cm2 cell
culture flask and allowed to reach confluence for 48-72 h. Confluent cells were treated
with As(III) and the cPKC inhibitor, Gö 6976 was added 1 h prior to and during As(III)
treatment wherever applicable. After completion of treatment, cells were rinsed with cold
PBS containing phosphatase inhibitors (1 mM β-glycerophosphate, 1 mM Sodium
pyrophosphate and 2.5 mM Sodium orthovanadate). The sodium orthovanadate was
activated for maximal inhibition of protein tyrosine phosphatases (activation method
obtained from the list of protocols provided by Upstate Cell Signaling Solutions). Cells
were harvested using cold 1X RIPA buffer (20 mM Tris, pH 7.5, 5 mM EDTA, 2 mM
EGTA, 1% Igepal, 0.1% SDS and 0.5% Deoxycholic acid) containing protease inhibitors
(Complete protease inhibitor cocktail tablet; Roche Diagnostics, Indianapolis, IN) and
phosphatase inhibitors. Cells were homogenized by sonication and centrifuged at 10,000
rpm for 15 min at 4 0C. The supernatant was sequentially incubated with 5 μg/ml each of
mouse anti-VE-cadherin monoclonal antibody followed by mouse anti-β-catenin
monoclonal antibody (Abcam, Cambridge, MA) for 24 h at 4 0C. Immune complexes
were precipitated using immobilized protein G (Pierce, Rockford, IL). After incubation
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for 2 h at 4 0C, the agarose bound immune complexes were washed three times with cold
1X RIPA buffer containing protease and phosphatase inhibitors and then heated at 70 0C
for 10 min in 1X solution of reducing agent and sample buffer (Invitrogen Life
Technologies, Carlsbad, CA).

3.3.7

Western blot analysis for VE-cadherin and β-catenin. The tyrosine

phosphorylation and tyrosine nitration of VE-cadherin and β-catenin was analyzed by
immunoprecipitation followed by Western blot. The immunoprecipitated proteins were
resolved using 4-12% NuPAGE Novex Bis-Tris gel (Invitrogen Life Technologies,
Carlsbad, CA), transferred to a polyvinylidenedifluoride (PVDF) membrane, blocked
with 5% BSA/TBST (TBST: 1.57 gm/l Tris HCl (pH=8), 8.76 gm/l NaCl, 500 μl/l Tween
20) for 1 h at RT and incubated with 2 μg/ml mouse anti-phosphotyrosine monoclonal
antibody (BD Transduction Laboratories, San Jose, CA) or 2 μg/ml rabbit antinitrotyrosine polyclonal antibody overnight at 4 0C in 1% BSA/TBST solution. This was
followed by incubation of the membrane with 1 μg/ml peroxidase labeled horse antimouse or 5 μg/ml goat anti-rabbit secondary antibody (Vector laboratories Inc.,
Burlingame, CA) for 1 h at RT in 1% BSA/TBST solution. The protein bands were
visualized by ECL Western blot detection system (Amersham, Buckinghamshire,
England). To quantitate tyrosine phosphorylation and tyrosine nitration, the total protein
content of immunoprecipitated VE-cadherin and β-catenin was determined as follows.
After analysis of phosphotyrosine and nitrotyrosine content, the membranes were
stripped at 60 0C for 1 h using stripping buffer (100 mM β-mercaptoethanol, 2% SDS and
62.5 mM Tris HCL, pH 6.8), blocked with 5% non-fat milk/TBST for 1 h at RT and

92

reprobed for VE-cadherin and β-catenin protein using 1.25 μg/ml rabbit anti-VE-cadherin
and 1 μg/ml rabbit anti-β-catenin polyclonal antibody (Cayman Chemicals, Ann Arbor,
MI) overnight at 4 0C in 0.4% non-fat milk/TBST. This was followed by incubation with
5 μg/ml peroxidase labeled goat anti-rabbit secondary antibody for 1 h at RT in 0.4%
non-fat milk/TBST, and the protein bands were visualized as previously described.
To determine the protein content of VE-cadherin without immunoprecipitation,
cells were rinsed with PBS and harvested with 1X RIPA buffer containing protease
inhibitors. Cells were homogenized with 18- and 25-gauge needles and boiled for 10 min.
Protein concentrations were determined by using the Bradford protein assay (Biorad,
Hercules, CA). The proteins were resolved using 4-12% NuPAGE Novex Bis-Tris gel,
transferred to PVDF membrane, blocked with 5% non-fat milk/TBST for 2 h at RT and
probed for VE-cadherin protein using 1.25 μg/ml rabbit anti-VE-cadherin polyclonal
antibody for 2 h at RT or overnight at 4 0C in 0.4% non-fat milk/TBST. This was
followed by incubation with 5 μg/ml peroxidase labeled goat anti-rabbit secondary
antibody for 1 h at RT in 0.4% non-fat milk/TBST. The protein bands were visualized by
ECL Western blot detection system. Protein loading was normalized using β-actin as
loading control. β-actin protein was detected using 0.24 μg/ml mouse anti-β-actin
monoclonal antibody (Abcam, Cambridge, MA) and 1 μg/ml peroxidase labeled horse
anti-mouse as the secondary antibody.

3.3.8

Western blot analysis for PKCα and β1. HAECs were seeded at a density of

7.5x105 cells in 25 or 75 cm2 cell culture flasks and after 3-5 days, confluent cells were
treated with As(III). Treatments of FeTPPS, L-NAME, Gö 6976 and BAPTA-AM (1,2-
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bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester) were applied
with or without As(III) wherever applicable. Cells were rinsed with cold PBS, harvested
using homogenizing buffer (50 mM Tris HCl, pH 7.5, 1 mM EDTA and protease
inhibitors) and sonicated. To separate the membrane and cytosolic fractions, the lysates
were centrifuged at 100,000x g for 1 h at 4 0C. The supernatant was collected as the
cytosolic fraction. The pellet was dissolved in 1X RIPA buffer containing protease
inhibitors, sonicated and centrifuged again at 100,000x g for 1 h at 4 0C. The supernatant
was the membrane fraction. Protein concentrations were determined by using the
Bradford protein assay. The proteins were resolved using 4-12% NuPAGE Novex BisTris gels. To detect good quality protein bands, different amounts of cytosolic and
membrane fraction proteins were loaded; 10-20 μg protein for the cytosolic fraction and
40-55 μg protein for the membrane fraction. After separation, the proteins were
transferred to PVDF membranes, blocked with 5% non-fat milk/TBST for 1 h at RT and
probed for PKCα or PKCβ1 protein using 0.4 μg/ml mouse anti-PKCα or mouse antiPKCβ1 monoclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) overnight
at 4 0C in 0.4% non-fat milk/TBST. This was followed by incubation with 1 μg/ml horse
anti-mouse secondary antibody conjugated with horseradish peroxidase for 1 h at RT in
0.4% non-fat milk/TBST. Protein bands were visualized by ECL Western blot detection
system. Na+/K+ ATPase was used as loading control for the membrane fraction using 0.4
μg/ml mouse anti-Na+/K+ ATPase monoclonal antibody (Upstate Cell Signaling
Solutions, Lake placid, NY) and GAPDH was used as loading control for the cytosolic
fraction using 1 μg/ml mouse anti-GAPDH monoclonal antibody (Chemicon
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International, Inc., Temecula, CA). In both cases, 1 μg/ml horse anti-mouse secondary
antibody was used.

3.3.9

Statistical analysis. Results are presented as means ± standard error of the mean

(SEM). When required, data was normalized with its respective control in order to
exclude differences in background conditions. Statistical analysis was performed using
Student’s t test when comparing two groups or Bonferroni method for comparing three
groups or more. When using the Bonferroni method, the alpha level of each individual
test was adjusted downwards to ensure that the overall experiment wise-risk remains at
0.05. Statistical analysis was performed using GraphPad Prism, version 4.00. Alpha error
was set at p<0.05.

3.4

Results

3.4.1

Cell viability after As(III) treatment

Cell viability was assessed using the MTT assay that is based on the reduction of yellow
MTT to purple formazan by metabolically active cells. The effect of 0.5, 1, 2.5, 5, 10, 25,
50, 100, 250 or 500 μM concentrations of As(III) on HAEC viability was determined at
12, 24 and 48 h. The IC50 and threshold values are represented in Table. 2. IC50
represents the concentration at which cell viability was reduced by 50% and threshold
value represents the concentration at which no toxicity was observed at that particular
time point. A maximum concentration of 10 μM As(III) was used in all the experiments
for a time period not exceeding 24 h. No toxicity was observed at the concentration and
time points used in our experiments.
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3.4.2

Effect of As(III) on peroxynitrite formation

Peroxynitrite induces nitration of tyrosine residues in proteins resulting in the formation
of 3-nitrotyrosine that is a stable adduct (Ischiropoulos, 1998, Beckman et al., 1994,
Beckman and Koppenol, 1996, Beckman, 1996). Peroxynitrite generation in HAECs with
1, 5 and 10 μM As(III) treatment was analyzed at 1, 6 and 24-h time points by
immunofluorescence detection of 3-nitrotyrosine. No changes in 3-nitrotyrosine levels
were observed in the HAECs. The data for the 24-h time point has been shown (Fig.
10A). However, a significant increase in 3-nitrotyrosine was observed in BAECs treated
with 10 μM As(III) for 24 h (Fig. 10B).
Our laboratory has previously shown that 1 h As(III) treatment induces
peroxynitrite formation in BAECs using the hydroethidine assay (Bunderson et al., 2002).
Hydroethidine is oxidized to the fluorescent product ethidium with reactive species such
as hydrogen peroxide, hydroxyl radical and peroxynitrite. Reaction of hydroethidine with
intracellular superoxide results in the formation of 2-hydroxyethidium, which is very
distinct from ethidium (Zhao et al., 2005, Zhao et al., 2003). Treatment of HAECs with 1,
5 and 10 μM As(III) for 1 h showed an increasing trend in peroxynitrite formation with
10 μM As(III), but it was not statistically significant. Exposure of cells to the
peroxynitrite decomposition catalyst, FeTPPS (10 μM), during 10 μM As(III) treatment
reduced the peroxynitrite formed to basal levels. No change was observed with 1 and 5
μM As(III) treatment (Fig. 10C). The effect of FeTPPS on cell viability was assessed
using the MTT assay and no loss of viability was observed at concentrations 1 μM-50 μM
up to 24 h (data not shown).
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3.4.3

Dose response of HAECs to cPKC inhibitor Gö 6976

The indolocarbazole Gö 6976 has been shown to be a potent and selective inhibitor of
cPKCs via interference with binding of ATP to the kinase (Martiny-Baron et al., 1993).
Preliminary experiments using HAECs at 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h and 6 h
revealed that 10 μM As(III) induces intercellular gaps beginning at 1 h of treatment that
were identified by immunofluorescence staining of VE-cadherin. To determine the
effective concentration of Gö 6976 to be used in our experiments, cells were exposed to
10 μM As(III) alone or to 10 nM, 50 nM, 100 nM, 250 nM, 500 nM and 1 μM Gö 6976
in the presence of 10 μM As(III) as depicted in Fig. 11. The duration of As(III) treatment
was 1 h and the respective Gö 6976 treatments were applied 1 h prior to and during
As(III) treatment. As analyzed by immunofluorescence staining of VE-cadherin, 250 nM1 μM concentrations of Gö 6976 (Fig. 11F-H) were able to inhibit the As(III) induced
gap formation. Therefore, in all the further experiments, 250 nM Gö 6976 was used to
inhibit the activity of cPKCs. Also, the effect of Gö 6976 on cell viability was assessed
using the MTT assay and no loss of viability was observed at concentrations 10 nM-500
nM up to 24 h (data not shown).

3.4.4

Effect of As(III) on the activation of PKCα

The translocation of PKC from cytosol to the membrane is an important step in its
activation process (Newton, 2001). Therefore, the effect of As(III) on the activation of
cPKCs in HAECs was analyzed by separation of the cytosolic and membrane fractions
and determining the protein content in each fraction by Western blotting technique.
Preliminary experiments showed that 10 μM As(III) treatment induced translocation of
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PKCα from the cytosolic fraction to the membrane fraction at 1 h, but not with 15 min
As(III) treatment. Also, serum starvation of cells (only 1% serum in medium) for 24 h
followed by 1 h of 10 μM As(III) treatment showed a similar increase in PKCα levels in
the membrane fraction as with 10 μM As(III) treatment without serum starvation. Hence,
activation of cPKCs was analyzed at 1 h of As(III) treatment using medium containing
serum, which is the normal environment for endothelial cells. As(III) induced damage to
the endothelial monolayer was also observed starting at the 1-h time point. Therefore,
cells were exposed to 1, 5 and 10 μM As(III) and cPKC activation was analyzed at the 1h time point (Fig. 12). Treatment with 5 and 10 μM As(III) induced a significant increase
in PKCα activation as determined by quantifying the protein content in the membrane
fraction (Figs. 12A and B). No change was observed with 1 μM As(III) treatment. In the
cytosolic fraction, a decrease in the PKCα content was observed with increasing As(III)
concentration indicative of PKCα translocation from the cytosol to the membrane (Figs.
12C and D). Treatment of the cells with 250 nM Gö 6976 for 1 h or with 20 μM BAPTAAM for 30 min, prior to and during 10 μM As(III) treatment inhibited the PKCα
activation as analyzed in the membrane fraction (Figs. 12E and F). The acetoxymethyl
(AM) ester derivatives are cell permeable and hence BAPTA-AM was used as an
intracellular Ca2+ chelator. The cytosolic fraction showed a corresponding change (Figs.
12G and H). An exact proportionate change in the cytosolic fraction was not evident
compared to the membrane fraction, but overall, protein levels were much greater in the
cytosolic fraction than the membrane fraction. Phorbol esters are very potent activators of
PKCs (Newton, 2001) and hence phorbol 12-myristate 13-acetate (PMA) was used as a
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positive control. Treatment with 1 μM PMA for 1 h induced a robust activation of PKCα
in the membrane fraction (Fig. 13).
PKCα is activated in a Ca2+-dependent manner (Newton, 2001). The effect of
Ca2+ ionophore, A23187, on PKCα activation was analyzed. Cells were treated with 10
μM A23187 for 10 min or with 20 μM BAPTA-AM for 30 min prior to and during
A23187 treatment. Activation of PKCα in the membrane fraction was observed with
A23187 that was inhibited by BAPTA-AM (Fig. 14). This also confirmed the function of
BAPTA-AM as an intracellular Ca2+ chelator.

3.4.5

Effect of L-NAME and FeTPPS on As(III)-induced activation of PKCα

As(III) treatment in HAECs showed no peroxynitrite formation. This was further
confirmed by analyzing the effect of the nitric oxide synthase inhibitor, L-NAME, and
the peroxynitrite decomposition catalyst, FeTPPS, on activation of PKCα. Peroxynitrite is
formed by the reaction between superoxide and nitric oxide. L-NAME impedes the
formation of nitric oxide by inhibiting nitric oxide synthase, thereby limiting
peroxynitrite formation. Cells were treated with 10 μM As(III) for 1 h or with 50 μM LNAME for 1 h prior to and during As(III) treatment. Activation of PKCα was observed
with As(III) treatment but no change was observed with L-NAME treatment (Figs. 15A
and B). The effect of L-NAME on cell viability was assessed using the MTT assay and
no loss of viability was observed at concentrations 10 μM-75 μM up to 24 h (data not
shown). Treatment with 10 μM FeTPPS during 10 μM As(III) exposure for 1 h also
showed no change in PKCα levels in the membrane fraction (Figs. 16A and B).
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3.4.6

Effect of As(III) on the activation of PKCβ1

The PKCβ gene consists of alternatively spliced variants, PKCβ1 and β2. Blobe et al.
(1996) have demonstrated that the β1 and β2 isoforms display similar requirements for
activation cofactors, phosphorylate substrates in an identical manner and are also
inhibited to a similar extent. In addition, the kinetics of translocation to the membrane as
well as down-regulation with PMA treatment was similar for both isoforms. Therefore,
we initially analyzed the effect of As(III) on PKCβ1 activation by determining its
translocation from the cytosol to the membrane. Control and 10 μM As(III) treated
samples that were used in analyzing PKCα levels were used to detect PKCβ1 activation.
The presence of PKCβ1 was only detected in the cytosolic fraction and no protein was
detected in the membrane fraction at the 1-h time point (Fig. 17). Since, no activation of
PKCβ1 was detected, the effect of As(III) on PKCβ2 was not analyzed.

3.4.7

Effect of As(III) on tyrosine phosphorylation of VE-cadherin and β-catenin

The association of VE-cadherin with β-catenin is critical for the stability of adherens
junctions, and tyrosine phosphorylation of either one or both proteins can alter
endothelial integrity. As(III)-induced disruption of the endothelial monolayer was evident
starting at the 1-h time point. Therefore, the effect of As(III) exposure on tyrosine
phosphorylation

of

VE-cadherin

and

β-catenin

was

analyzed

at

1

h

by

immunoprecipitation followed by Western blotting. The phosphorylation of β-catenin
was determined by probing the membrane with anti-phosphotyrosine monoclonal
antibody following electrophoresis (Fig. 18A). The same membrane was stripped and
total β-catenin protein content was analyzed (Fig. 18B). The tyrosine phosphorylation
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levels were determined by normalizing with the total β-catenin protein content (Fig.
18C). A concentration-dependent effect of As(III) exposure on tyrosine phosphorylation
of β-catenin was observed. Treatment of cells with 1 μM As(III) showed no change in
tyrosine phosphorylation as compared to the control (untreated), whereas an increasing
trend in tyrosine phosphorylation was observed with 5 μM As(III), and 10 μM As(III)
treatment resulted in a significant increase in tyrosine phosphorylation of β-catenin. The
increase in tyrosine phosphorylation induced by 10 μM As(III) was completely inhibited
by 250 nM Gö 6976 (Fig. 18C).
No tyrosine phosphorylation of VE-cadherin was observed (Fig. 18D). Even a
basal level of tyrosine phosphorylation could not be detected. Increasing the
concentrations of phosphatase inhibitors in the lysis buffer to confirm that VE-cadherin
was not dephosphorylated during harvesting or immunoprecipitation did not yield any
positive results. Analysis of the total VE-cadherin protein content established the
presence of VE-cadherin and confirmed the adequacy of immunoprecipitation and
Western blotting (Fig. 18E).

3.4.8

Effect of As(III) on tyrosine nitration of VE-cadherin and β-catenin

Peroxynitrite has been shown to induce nitration of β-catenin and cause disruption of the
endothelial monolayer (Knepler et al., 2001). Although peroxynitrite generation was not
observed with As(III) treatment, we analyzed the nitration of VE-cadherin and β-catenin.
HAECs were treated with 10 μM As(III) for 1, 6 and 24 h, and tyrosine nitration was
determined by immunoprecipitation followed by Western blotting. Tyrosine nitrated
bovine serum albumin (BSA) was used as a positive control (Fig 19A). The tyrosine
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nitration of VE-cadherin (Fig. 19B) and β-catenin (Fig. 19C) was determined by probing
the membrane with anti-nitrotyrosine polyclonal antibody following electrophoresis. The
same membranes were stripped and total VE-cadherin and β-catenin protein content was
analyzed. No tyrosine nitration of VE-cadherin or β-catenin was detected at any time
point. Analysis of the total VE-cadherin and β-catenin protein content established the
presence of the proteins and confirmed the adequacy of immunoprecipitation and
Western blotting. This further assured that tyrosine phosphorylation and not nitration was
the main event following As(III) exposure.

3.4.9

Effect of As(III) on VE-cadherin localization and intercellular gap formation

Based on results from preliminary experiments, the concentration- and time-dependent
effects of As(III) on VE-cadherin localization and intercellular gap formation were
analyzed by immunofluorescence staining of VE-cadherin. Cells were treated with 1, 5
and 10 μM As(III) for 1, 6, 12 and 24 h. At the 1-h time point (Fig. 20), the frequency of
gap formation observed with 10 μM As(III) treatment (Fig. 20D) was much greater than 5
μM As(III) (Fig. 20C) and only a few gaps were observed with 1 μM As(III) treatment
(Fig. 20B) as compared to the untreated cells (Fig. 20A). Cells appeared to be pulling
apart from the adjacent cells. Some areas of undamaged monolayer could be observed.
Also, non-uniform staining of VE-cadherin was observed where the gaps appeared. To
corroborate the fact that the observed effects were not due to cells undergoing apoptosis,
immunofluorescence staining for cleaved caspase-3 was performed. Figs 20E and F
demonstrate little cleaved caspase-3 staining for either untreated or 10 μM As(III) treated
cells, respectively. The cPKC inhibitor, Gö 6976, inhibited gap formation at all
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concentrations of As(III) treatment and uniform distribution of VE-cadherin could be
observed at cell-cell junctions. The images of 250 nM Gö 6976 treatment alone (Fig.
20G) and 10 μM As(III) + 250 nM Gö 6976 treatment (Fig. 20H) are shown. As with
As(III) treatment, little and similar cleaved caspase-3 staining was observed for 250 nM
Gö 6976 treatment alone and 10 μM As(III) + 250 nM Gö 6976 treatment (data not
shown).
At the 6-h time point (Fig. 21), a similar concentration-dependent effect of As(III)
was observed but the size and frequency of gaps were greater than that observed at the 1
h time point. Exposure to 1 μM (Fig. 21B) and 5 μM As(III) (Fig. 21C) revealed nonuniform staining of VE-cadherin where the gaps appeared whereas treatment with 10 μM
As(III) (Fig. 21D) resulted in loss of VE-cadherin staining at the cell-cell junctions.
Immunofluorescence staining of cleaved caspase-3 in untreated (Fig. 21E) and 10 μM
As(III) treated cells (Fig. 21F) revealed no differences in apoptosis. Also, Gö 6976
inhibited gap formation at all concentrations of As(III) treatment and restored VEcadherin staining at the cell-cell junctions. The images of 250 nM Gö 6976 alone (Fig.
21G) and 10 μM As(III) + 250 nM Gö 6976 treatment (Fig. 21H) are shown. As with
As(III), little and similar cleaved caspase-3 staining was observed for 250 nM Gö 6976
treatment alone and 10 μM As(III) + 250 nM Gö 6976 treatment (data not shown).
At the 12-h (Fig. 22A-H) and 24-h (Fig. 23A-H) time points, the concentrationdependent effects of As(III) treatment were similar to those seen at earlier time points.
However, the frequency and size of gaps observed were maximal at the 6-h time point.

103

3.4.10 Effect of As(III) treatment on VE-cadherin protein content
The immunofluorescence results in Figs. 20-23 showed that VE-cadherin distribution was
altered by As(III) exposure. Therefore, the effects of 1, 5, and 10 μM As(III) treatments
on the protein levels of VE-cadherin at the 24-h time point were determined. Western
blotting analysis revealed a concentration-dependent effect of As(III) on VE-cadherin
protein levels in the HAECs (Figs. 24A and B). Approximately 8, 15 and 30% reductions
in VE-cadherin protein were observed with 1, 5 and 10 μM As(III) treatment,
respectively, compared to the control (untreated) HAECs (Fig. 24B).

3.4.11 Effect of As(III) exposure on β-catenin localization
The cytoplasmic domain of VE-cadherin is linked with β-catenin, so it was of interest to
determine whether As(III) affects β-catenin distribution. Exposure to As(III) for 6 h
revealed the most damaging effects on the endothelial monolayer. Hence, the effect of
As(III)

treatment

on

β-catenin

localization

in

HAECs

was

analyzed

by

immunofluorescence staining at the 6-h time point (Fig. 25). As previously observed with
VE-cadherin localization, β-catenin staining showed a corresponding concentrationdependent effect with As(III) treatment. The frequency of gap formation with 10 μM
As(III) (Fig. 25D) was greater than 5 μM As(III) (Fig. 25C) and only a few gaps were
observed with 1 μM As(III) treatment (Fig. 25B). Non-uniform distribution or loss of βcatenin staining was evident wherever gaps could be observed. Also, 250 nM Gö 6976
treatment inhibited the gap formation induced by 10 μM As(III) (Fig. 25E) and restored
the β-catenin staining at cell-cell junctions.
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3.4.12 Effect of As(III) exposure on the formation of stress fibers
The cadherin/β-catenin complex is associated with the actin cytoskeleton, and this
association is very important for maintaining junctional stability and structural integrity
of the endothelial cell monolayer. As previously mentioned, reorganization of actin
microfilaments into stress fibers can adversely affect monolayer integrity. Hence, the
effects of 1, 5 and 10 μM As(III) on reorganization of actin microfilaments were analyzed
at 1, 6, 12 and 24 h by immunofluorescence staining using fluorophore-conjugated
phalloidin. A concentration- and time-dependent effect of As(III) treatment was
observed. At the 1-h time point (Fig. 26), As(III) induced a concentration-dependent
increase in stress fibers with the maximum stress fibers being observed with 10 μM
As(III) treatment (Fig. 26D). Treatment with Gö 6976 abolished the stress fiber formation
at all concentrations of As(III) treatment. The images of 250 nM Gö 6976 treatment alone
(Fig. 26E) and 10 μM As(III) + 250 nM Gö 6976 treatment (Fig. 26F) are shown.
At the 6-h time point (Fig. 27), the frequency and density of stress fibers induced
by As(III) was much higher than that observed at the 1-h time point. Also, a
concentration-dependent increase in stress fibers was observed with the maximum stress
fibers being induced with 10 μM As(III) treatment (Fig. 27D). Treatment with Gö 6976
reduced the stress fibers at all concentrations of As(III) treatment. The images of 250 nM
Gö 6976 treatment alone (Fig. 27E) and 10 μM As(III) + 250 nM Gö 6976 treatment
(Fig. 27F) are shown.
At the 12-h (Fig. 28A-F) and 24-h (Fig. 29A-F) time points, similar
concentration-dependent effects of As(III) treatment were observed. Stress fiber
formation, like the intercellular gap formation, was maximal at the 6-h time point.
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3.4.13 Effect of As(III) on endothelial permeability
Exposure to As(III) caused detrimental effects on the endothelial monolayer and induced
reorganization of actin microfilaments into stress fibers. Therefore, we hypothesized that
As(III) would also increase endothelial permeability. The effect of 1, 5 and 10 μM As(III)
treatment on endothelial permeability was analyzed at the 6-h time point (Fig. 30).
Confluent monolayers of HAECs grown on Transwell inserts were treated with various
As(III) concentrations, and the permeability of the monolayer for FITC-dextran was
determined by measuring the fluorescence intensity of the medium in the plate well. A
5% increase in permeability was observed with 1 and 5 μM As(III) treatment, whereas 10
μM As(III) induced approximately a 19% increase. Treatment with 250 nM Gö 6976
inhibited the increase in permeability induced by 10 μM As(III).
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3.5

Figures

Table. 2. Cell viability after As(III) treatment
Time

12 h

24 h

48 h

IC50

103 μM

40 μM

23 μM

Threshold

50 μM

10 μM

5 μM

Table. 2. Cell viability after As(III) treatment. HAECs were treated with As(III) up to
500 μM for 12, 24 and 48 h. Cell viability was determined using the MTT colorimetric
assay.
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Fig. 10. Effect of As(III) on peroxynitrite formation
A.

B.

C.
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Fig. 10. Effect of As(III) on peroxynitrite formation. (A) Confluent HAECs were treated
with 1, 5 and 10 μM As(III) for 24 h and the formation of 3-nitrotyrosine was analyzed
by immunofluorescence. The control (100%) is indicated by dotted line and the graph is
representative of 2 independent experiments performed. (B) Confluent BAECs were
treated with 10 μM As(III) for 24 h and the formation of 3-nitrotyrosine was analyzed by
immunofluorescence quantification. Error bars represent mean ± SEM for n=3 and *
indicates significantly different from control with p<0.05. (C) Confluent HAECs were
treated with 1, 5 and 10 μM As(III) or 10 μM FeTPPS in the presence of 10 μM As(III)
for 1 h and the formation of peroxynitrite was analyzed based on the oxidation of
hydroethidine to ethidium. Error bars represent mean ± SEM for n=4-5.
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Fig. 11. Dose response of HAECs to cPKC inhibitor Gö 6976

Fig. 11. Dose response of HAECs to cPKC inhibitor Gö 6976. Confluent HAEC
monolayers were either untreated (A) or treated with 10 μM As(III) (B) for 1 h and the
intercellular gaps (indicated with arrows) were visualized by immunofluorescence
staining of VE-cadherin (green). The nuclei were stained with Hoechst (blue). Pretreating
the cells with increasing concentration of Gö 6976 for 1 h prior to and during 10 μM
As(III) treatment inhibited the gap formation in a concentration-dependent manner: 10
μM As(III) + 10 nM Gö 6976 (C), 10 μM As(III) + 50 nM Gö 6976 (D), 10 μM As(III) +
100 nM Gö 6976 (E), 10 μM As(III) + 250 nM Gö 6976 (F), 10 μM As(III) + 500 nM Gö
6976 (G) and 10 μM As(III) + 1 μM Gö 6976 (H). Magnification=60X. The images are
representative of 3 independent experiments performed.
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Fig. 12. Effect of As(III) on the activation of PKCα

B.
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D.
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E.

F.
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G.

H.
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Fig. 12. Effect of As(III) on the activation of PKCα. Confluent HAECs were treated with
1, 5, and 10 μM As(III) for 1 h or pretreated with 250 nM Gö 6976 and 20 μM BAPTAAM for 1 h and 30 min, respectively, prior to and during 10 μM As(III) treatment. The
lysates were subjected to ultracentrifugation to separate the membrane and cytosolic
fractions and the PKCα levels in both fractions were determined by Western blotting. The
PKCα content in the membrane fraction is shown in (A and E) upper panel and the lower
panel represents the Na+/K+ ATPase loading control for the membrane fraction. The
percent change in PKCα content in the membrane fraction relative to the control
(untreated) is represented in (B and F). The PKCα content in the cytosolic fraction is
shown in (C and G) upper panel and the lower panel represents the GAPDH loading
control for the cytosolic fraction. The percent change in PKCα content in the cytosolic
fraction relative to the control is represented in (D and H). The images in (A, C, E and G)
are representative of 3-6 independent experiments performed. The control (100%) is
indicated by the dotted line in (B, D, F and H). Error bars represent mean ± SEM for n=36. * and # indicates significantly different from control and 10 μM As(III), respectively,
with p<0.05.
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Fig. 13. Effect of As(III) and PMA on the activation of PKCα

Fig. 13. Effect of As(III) and PMA on the activation of PKCα. Confluent HAECs were
treated with 10 μM As(III) or the positive control 1 μM PMA for 1 h. The lysates were
subjected to ultracentrifugation to separate the membrane and cytosolic fractions and the
PKCα levels were determined by Western blotting. The PKCα content in the membrane
fraction is shown. The image is from one experiment performed.
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Fig. 14. Effect of A23187 on the activation of PKCα

Fig. 14. Effect of A23187 on activation of PKCα. Confluent HAECs were treated with 10
μM A23187 for 10 min or pretreated with 20 μM BAPTA-AM for 30 min prior to and
during 10 μM A23187 treatment. The lysates were subjected to ultracentrifugation to
separate the membrane and cytosolic fractions and the PKCα levels were determined by
Western blotting. The PKCα content in the membrane fraction is shown in the upper
panel and the lower panel represents the Na+/K+ ATPase loading control for the
membrane fraction. The image is from one experiment performed.
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Fig. 15. Effect of L-NAME on As(III)-induced activation of PKCα
A.

B.

Fig. 15. Effect of L-NAME on As(III)-induced activation of PKCα. Confluent HAECs
were treated with 10 μM As(III) for 1 h or pretreated with 50 μM L-NAME for 1 h prior
to and during As(III) treatment. The lysates were subjected to ultracentrifugation to
separate the membrane and cytosolic fractions and the PKCα levels in both fractions were
determined by Western blotting. The PKCα content in the membrane fraction is shown in
(A) upper panel and the lower panel represents the Na+/K+ ATPase loading control for
the membrane fraction. The percent change in PKCα content in the membrane fraction
relative to the control (untreated) is represented in (B). The control (100%) is indicated
by the dotted line in (B). The image (A) is representative of 5-6 independent experiments
performed. Error bars represent mean ± SEM for n=5-6. * indicates significantly different
from control with p<0.001.
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Fig. 16. Effect of FeTPPS on As(III)-induced activation of PKCα
A.

B.

Fig. 16. Effect of FeTPPS on As(III)-induced activation of PKCα. Confluent HAECs
were treated with 10 μM As(III) or 10 μM FeTPPS in the presence of 10 μM As(III) for 1
h. The lysates were subjected to ultracentrifugation to separate the membrane and
cytosolic fractions and the PKCα levels were determined by Western blotting. The PKCα
content in the membrane fraction is shown in (A) upper panel and the lower panel
represents the Na+/K+ ATPase loading control for the membrane fraction. The percent
change in PKCα content in the membrane fraction relative to the control (untreated) is
represented in (B). The control (100%) is indicated by the dotted line in (B). The image
(A) is representative of 2 independent experiments performed.
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Fig. 17. Effect of As(III) on the activation of PKCβ1

Fig. 17. Effect of As(III) on the activation of PKCβ1. Confluent HAECs were treated with
10 μM As(III) for 1 h. The lysates were subjected to ultracentrifugation to separate the
membrane and cytosolic fractions and the PKCβ1 levels in both fractions were
determined by Western blotting. The image is representative of 2 independent
experiments performed.
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Fig. 18. Effect of As(III) on tyrosine phosphorylation of β-catenin and VE-cadherin

C.
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Fig. 18. Effect of As(III) on tyrosine phosphorylation of β-catenin and VE-cadherin.
Confluent HAECs were treated with 1, 5, and 10 μM As(III) for 1 h or pretreated with
250 nM Gö 6976 for 1 h prior to and during 10 μM As(III) treatment. The β-catenin was
immunoprecipitated, and Western blotting technique was used to analyze the
phosphorylation of tyrosine residues (A). The membrane was stripped and reprobed to
determine the total β-catenin protein content (B). The images A and B are representative
of 4-6 independent experiments performed. The percent change in tyrosine
phosphorylation with the various treatments relative to the control (untreated) is
represented in (C). The control (100%) is indicated by the dotted line. Error bars
represent mean ± SEM for n=4-6. * and # indicates significantly different from control
and 10 μM As(III), respectively, with p<0.05. Similarly, the VE-cadherin protein was
immunoprecipitated, and Western blotting technique was used to analyze the
phosphorylation of tyrosine residues (D). The membrane was stripped and reprobed to
determine the total VE-cadherin protein content (E). The images D and E are
representative of 2 independent experiments performed.
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Fig. 19. Effect of As(III) on tyrosine nitration of VE-cadherin and β-catenin

Fig. 19. Effect of As(III) on tyrosine nitration of VE-cadherin and β-catenin. Confluent
HAECs were treated with 10 μM As(III) for 1, 6 and 24 h. The VE-cadherin and βcatenin proteins were immunoprecipitated, and Western blotting technique was used to
analyze the nitration of tyrosine residues (B and C upper panel). The membranes were
stripped and reprobed to determine the total VE-cadherin and β-catenin protein content
(B and C lower panel). The images in A, B and C are from one experiment performed.
Nitrated BSA was used as a positive control (A).
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Fig. 20. Effect of As(III) on VE-cadherin localization and intercellular gap
formation at the 1-h time point

Fig. 20. Effect of As(III) on VE-cadherin localization and intercellular gap formation at
the 1-h time point. Confluent HAEC monolayers were either untreated (A) or treated with
1 μM As(III) (B), 5 μM As(III) (C) and 10 μM As(III) (D) for 1 h and the intercellular
gaps (indicated with arrows) induced with As(III) treatment were visualized by
immunofluorescence staining of VE-cadherin (green). The nuclei were stained with
Hoechst (blue). Cleaved caspase-3 staining (green) for untreated (E) and 10 μM As(III)
(F) treated cells is indicated by arrowheads. Pretreatment with 250 nM Gö 6976 for 1 h
prior to and during 10 μM As(III) treatment (H) inhibited the As(III) induced gaps
whereas 250 nM Gö 6976 treatment alone (G) did not have any effect on the endothelial
monolayer. Magnification=60X. The images are representative of 4 independent
experiments performed.
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Fig. 21. Effect of As(III) on VE-cadherin localization and intercellular gap
formation at the 6-h time point.

Fig. 21. Effect of As(III) on VE-cadherin localization and intercellular gap formation at
the 6-h time point. Confluent HAEC monolayers were either untreated (A) or treated with
1 μM As(III) (B), 5 μM As(III) (C) and 10 μM As(III) (D) for 6 h and the intercellular
gaps (indicated with arrows) induced with As(III) treatment were visualized by
immunofluorescence staining of VE-cadherin (green). The nuclei were stained with
Hoechst (blue). Cleaved caspase-3 staining (green) for untreated (E) and 10 μM As(III)
(F) treated cells is indicated by arrowheads. Pretreatment with 250 nM Gö 6976 for 1 h
prior to and during 10 μM As(III) treatment (H) inhibited the As(III) induced gaps
whereas 250 nM Gö 6976 treatment alone (G) did not have any effect on the endothelial
monolayer. Magnification=60X. The images are representative of 4 independent
experiments performed.
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Fig. 22. Effect of As(III) on VE-cadherin localization and intercellular gap
formation at the 12-h time point.

Fig. 22. Effect of As(III) on VE-cadherin localization and intercellular gap formation at
the 12-h time point. Confluent HAEC monolayers were either untreated (A) or treated
with 1 μM As(III) (B), 5 μM As(III) (C) and 10 μM As(III) (D) for 12 h and the
intercellular gaps (indicated with arrows) induced with As(III) treatment were visualized
by immunofluorescence staining of VE-cadherin (green). The nuclei were stained with
Hoechst (blue). Cleaved caspase-3 staining (green) for untreated (E) and 10 μM As(III)
(F) treated cells is indicated by arrowheads. Pretreatment with 250 nM Gö 6976 for 1 h
prior to and during 10 μM As(III) treatment (H) inhibited the As(III) induced gaps
whereas 250 nM Gö 6976 treatment alone (G) did not have any effect on the endothelial
monolayer. Magnification=60X. The images are representative of 4 independent
experiments performed.
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Fig. 23. Effect of As(III) on VE-cadherin localization and intercellular gap
formation at the 24-h time point

Fig. 23. Effect of As(III) on VE-cadherin localization and intercellular gap formation at
the 24-h time point. Confluent HAEC monolayers were either untreated (A) or treated
with 1 μM As(III) (B), 5 μM As(III) (C) and 10 μM As(III) (D) for 24 h and the
intercellular gaps (indicated with arrows) induced with As(III) treatment were visualized
by immunofluorescence staining of VE-cadherin (green). The nuclei were stained with
Hoechst (blue). Cleaved caspase-3 staining (green) for untreated (E) and 10 μM As(III)
(F) treated cells is indicated by arrowheads. Pretreatment with 250 nM Gö 6976 for 1 h
prior to and during 10 μM As(III) treatment (H) inhibited the As(III) induced gaps
whereas 250 nM Gö 6976 treatment alone (G) did not have any effect on the endothelial
monolayer. Magnification=60X. The images are representative of 4 independent
experiments performed.
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Fig. 24. Effect of As(III) treatment on VE-cadherin protein content
A.

B.

Fig. 24. Effect of As(III) treatment on VE-cadherin protein content. Confluent HAECs
were treated with 1, 5 and 10 μM As(III) for 24 h and VE-cadherin protein content was
analyzed by Western blotting technique. The VE-cadherin protein content is shown in the
(A) upper panel and the lower panel represents the β-actin loading control. The images in
(A) are representative of 7 experiments performed. The percent change in VE-cadherin
protein relative to the control (untreated) is represented in (B). The control (100%) is
indicated by the dotted line in (B). Error bars represent mean ± SEM for n=7. * indicates
significantly different from control with p<0.05.
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Fig. 25. Effect of As(III) exposure on β-catenin localization

Fig. 25. Effect of As(III) exposure on β-catenin localization. Confluent HAECs were
either untreated (A) or treated with 1 μM As(III) (B), 5 μM As(III) (C) and 10 μM As(III)
(D) for 6 h and β-catenin localization was visualized by immunofluorescence staining
(green). Non-uniform staining or loss of β-catenin was observed wherever gaps occurred
(indicated by arrows). Pretreatment with 250 nM Gö 6976 for 1 h prior to and during 10
μM As(III) treatment (E) restored the β-catenin localization at cell-cell junctions. The
nuclei were stained with Hoechst (blue). Magnification=60X. The images are
representative of 3 independent experiments performed.
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Fig. 26. Effect of As(III) exposure on formation of stress fibers at the 1-h time point

Fig. 26. Effect of As(III) exposure on formation of stress fibers at the 1-h time point.
Confluent HAEC monolayers were either untreated (A) or treated with As(III); 1 μM (B),
5 μM (C) and 10 μM (D) for 1 h and the stress fibers induced with As(III) treatment were
visualized by immunofluorescence staining with Alexa Fluor 568-conjugated phalloidin
(red). Pretreatment with 250 nM Gö 6976 for 1 h prior to and during 10 μM As(III)
treatment (F) inhibited the As(III) induced stress fibers whereas 250 nM Gö 6976
treatment alone (E) did not have an effect on stress fiber formation. Magnification=60X.
The images are representative of 4 independent experiments performed.
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Fig. 27. Effect of As(III) exposure on formation of stress fibers at the 6-h time point

Fig. 27. Effect of As(III) exposure on formation of stress fibers at the 6-h time point.
Confluent HAEC monolayers were either untreated (A) or treated with As(III); 1 μM (B),
5 μM (C) and 10 μM (D) for 6 h and the stress fibers induced with As(III) treatment were
visualized by immunofluorescence staining with Alexa Fluor 568-conjugated phalloidin
(red). Pretreatment with 250 nM Gö 6976 for 1 h prior to and during 10 μM As(III)
treatment (F) reduced the As(III) induced stress fibers whereas 250 nM Gö 6976
treatment alone (E) did not have an effect on stress fiber formation. Magnification=60X.
The images are representative of 4 independent experiments performed.
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Fig. 28. Effect of As(III) exposure on formation of stress fibers at the 12-h time
point.

Fig. 28. Effect of As(III) exposure on formation of stress fibers at the 12-h time point.
Confluent HAEC monolayers were either untreated (A) or treated with As(III); 1 μM (B),
5 μM (C) and 10 μM (D) for 12 h and the stress fibers induced with As(III) treatment
were visualized by immunofluorescence staining with Alexa Fluor 568-conjugated
phalloidin (red). Pretreatment with 250 nM Gö 6976 for 1 h prior to and during 10 μM
As(III) treatment (F) inhibited the As(III) induced stress fibers whereas 250 nM Gö 6976
treatment alone (E) did not have an effect on stress fiber formation. Magnification=60X.
The images are representative of 4 independent experiments performed.
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Fig. 29. Effect of As(III) exposure on formation of stress fibers at the 24-h time point

Fig. 29. Effect of As(III) exposure on formation of stress fibers at the 24-h time point.
Confluent HAEC monolayers were either untreated (A) or treated with As(III); 1 μM (B),
5 μM (C) and 10 μM (D) for 24 h and the stress fibers induced with As(III) treatment
were visualized by immunofluorescence staining with Alexa Fluor 568-conjugated
phalloidin (red). Pretreatment with 250 nM Gö 6976 for 1 h prior to and during 10 μM
As(III) treatment (F) inhibited the As(III) induced stress fibers whereas 250 nM Gö 6976
treatment alone (E) did not have an effect on stress fiber formation. Magnification=60X.
The images are representative of 4 independent experiments performed.
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Fig. 30. Effect of As(III) on endothelial permeability

Fig. 30. Effect of As(III) on endothelial permeability. Confluent HAECs were treated
with 1, 5, and 10 μM As(III) for 6 h or pretreated with 250 nM Gö 6976 for 1 h prior to
and during 10 μM As(III) treatment. Monolayer permeability was measured using FITCdextran. The control (100%) is indicated by the dotted line. Error bars represent mean ±
SEM for n=4-5.
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3.6

Discussion
The results from this study show that PKCα is a key mediator in the proposed

mechanism for As(III)-induced atherosclerosis. The data shows that PKCα plays a crucial
role in localization of the adherens junction proteins, VE-cadherin and β-catenin, and in
regulating endothelial gap formation, stress fiber formation and vascular permeability.
As(III) treatment induced intercellular gaps thereby disrupting the endothelial monolayer
as evidenced by loss or non-uniform staining of VE-cadherin and β-catenin where the
gaps appeared. Reduced VE-cadherin protein content was also detected; a finding that
may in part be responsible for the observed intercellular gaps. An increased plasma
concentration of VE-cadherin has been associated with coronary atherosclerosis (Soeki et
al., 2004), and in vitro studies have shown that hydrogen peroxide induces internalization
of VE-cadherin and gap formation (Kevil et al., 1998). Hence, the decreased VE-cadherin
may be due to internalization and degradation or release into the cell culture medium.
β-catenin was found to be phosphorylated with 5 and 10 μM As(III) treatments,
but no tyrosine phosphorylation of VE-cadherin was detected. There are several nonreceptor tyrosine kinases such as Fyn, Fer, cMet, Abl and Src that have been shown to
associate with and modulate the phosphorylation state of β-catenin and its association
with cadherin (Lilien and Balsamo, 2005) during various developmental and
physiological processes. In particular, phosphorylation of β-catenin at tyrosine 654 by Src
has been shown to cause a fivefold reduction in its affinity for E-cadherin (Roura et al.,
1999), which belongs to the same class of type I classical cadherins as VE-cadherin
(Ivanov et al., 2001). The phosphorylation and dephosphorylation state of adherens
junction proteins plays a critical role in the formation and/or maintenance of stable cell-
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cell adhesions (Lilien and Balsamo, 2005, Schnittler, 1998). Therefore, tyrosine
phosphorylation of β-catenin could potentially reduce its affinity for association with VEcadherin and cause dissociation or loosening of the adherens junctions. As(III) has been
shown to stimulate Src kinase activity in intact endothelial cells, but not recombinant Src
activity (Barchowsky et al., 1999b). This suggests that As(III) does not affect Src activity
directly, but one or more intermediates likely exist between As(III) and Src activation,
one of which potentially could be PKC. Consistent with this, Chang et al. (2001) have
demonstrated that association of activated PKC with the anchoring protein, receptor for
activated C kinase, promotes its binding to Src tyrosine kinase. Therefore, a cooperative
interaction between PKC and Src is feasible. This may explain the tyrosine
phosphorylation of β-catenin as a consequence of PKC activation, which is a
serine/threonine kinase.
Arsenic has been shown to increase Ca2+-dependent PKC activity in Chinese
hamster ovary cells at high doses after 4-h treatment (Liu and Huang, 1997). Similarly,
transient activation of PKCα was observed with 20 μM arsenic treatment in a mouse
epidermal cell line (Chen et al., 2000). Our results showed that 5 and 10 μM As(III)
treatment induced significant activation of PKCα at the 1-h time point in a Ca2+dependent manner. The downstream effects of As(III)-induced PKCα activation were
confirmed by using the cPKC inhibitor, Gö 6976. Inhibition of PKCα prevented gap
formation and restored VE-cadherin and β-catenin at the cell-cell junctions. Tyrosine
phosphorylation of β-catenin induced by As(III) was also reduced to basal levels. The
effects of activation of PKCα and β on endothelial integrity in different
pathophysiological circumstances have been well documented (Yuan, 2003). Activation
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of PKCα by thrombin has been shown to modulate endothelial integrity by induction of
stress fibers and increased endothelial permeability (Sandoval et al., 2001). Also, tyrosine
phosphorylation of β-catenin has been observed that is cPKC-dependent (Cohen et al.,
1999). Activation of PKCβ1 was not detected with As(III) treatment. The PKCβ1 and β2
isoforms have been shown to follow similar activation/membrane translocation kinetics
in several cell lines using similar activators (Blobe et al., 1996, Goodnight et al., 1995,
Wang et al., 2004). Therefore, it appears that PKCα and not PKCβ plays a significant role
in As(III)-induced endothelial disruption.
Formation of stress fibers induced by As(III) was also abolished or reduced with
Gö 6976 treatment. Studies have demonstrated the relation between PKCα activation,
stress fiber formation and cell contraction. It has been found that PKCα induces the
activation of myosin by serine/threonine phosphorylation of myosin light chain, which
results in actin-myosin interaction and subsequent stress fiber formation and cell
contraction (Tiruppathi et al., 2003). Therefore, PKC inhibition plausibly inhibited the
contractile force exerted by the stress fibers. Confluent endothelial cells consist of a band
of actin filaments concentrated along the cell borders known as a dense peripheral band
(DPB) that is also present in vivo (Gabbiani et al., 1983, Schnittler, 1998). The cadherincatenin complex associates with the actin filaments of DPB, which is important for
junctional stability. Our results showed that actin filaments were present in untreated
cells along the cell borders and were mostly absent in central regions of the cell.
Treatment with As(III) resulted in loss of DPB and an increase in stress fibers traversing
the cells. The effect of As(III) was observed to be concentration- and time-dependent
with the maximum stress fibers being formed with 10 μM As(III) at the 6-h time point.
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Actin reorganization associated with disruption of the endothelial barrier is characterized
by increased stress fiber density and reduction or loss of DPB (Lum and Roebuck, 2001).
Stress fibers have the molecular machinery to generate contractile force and have been
associated with gap formation and increased endothelial permeability (Pellegrino et al.,
2004, Yuan, 2003).
Vascular permeability changes are associated with loss of endothelial integrity.
Chen et al. (2004) and Tsai et al. (2005) showed that As(III) alters endothelial
permeability in rodents. Using FITC-dextran, we found a 5% increase in endothelial
permeability with 1 and 5 μM As(III) and approximately a 19% increase with 10 μM
As(III) treatment that was inhibited by Gö 6976 treatment. These changes were not as
great as expected based on the gap formation observed and actin stress fiber formation.
However, Chen et al. (2004) and Tsai et al. (2005) have clearly demonstrated that even a
small increase in permeability could be pathologically important. Taken together, these
results suggest that As(III) induces tyrosine phosphorylation of β-catenin, which
modulates adherens junction assembly resulting in non-uniform distribution or loss of
VE-cadherin as well as β-catenin at the cell-cell junctions and promotes the formation of
stress fibers which culminates in intercellular gap formation and increased permeability.
As(III) has been shown to modulate several signaling pathways by generation of
oxidative and nitrosative stress in different cell systems such as BAECs and porcine
aortic endothelial cells (Barchowsky et al., 1996, Barchowsky et al., 1999a, Bunderson et
al., 2002). In particular, peroxynitrite and its donor, SIN-1, have been shown to induce
nitration of PKCα, actin as well as β-catenin and alter their function (Knepler et al., 2001,
Chakraborti et al., 2005, Knapp et al., 2001). We hypothesized, therefore, that As(III)-
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induced peroxynitrite may play a role in endothelial barrier modulation. However, no
peroxynitrite generation was observed with As(III) treatment in HAECs, although an
increase was observed in BAECs. This was confirmed by the absence of nitration of VEcadherin and β-catenin as well as an inability by a nitric oxide synthase inhibitor and a
peroxynitrite decomposition catalyst, L-NAME and FeTPPS, to inhibit PKCα activation.
The generation of reactive species with As(III) has been observed to be species specific.
For example, no nitric oxide formation was observed with As(III) (<5 μM) in porcine
aortic endothelial cells (Barchowsky et al., 1999a) whereas Kao et al. (2003),
demonstrated that As(III) (<5 μM) induces the production of nitric oxide in HUVECs.
The observed differences could also be attributed to different experimental conditions.
The differential effects of As(III) in the production of reactive species have been
reviewed in detail by Gurr et al. (2003) and Kumagai and Pi, (2004).
While the results presented here show PKCα dependency for the effects of As(III)
on endothelial cell-cell adhesion, monolayer integrity and vascular permeability, they do
not suggest that As(III) effects on endothelium are restricted to the PKCα pathway. Other
signal transduction pathways intersect with PKCα signaling. The PKC enzymes are
serine/threonine kinases, and it has been suggested that crosstalk exists between the
tyrosine and serine/threonine kinase signaling cascades (Bauman and Scott, 2002, Chang
et al., 2001). Involvement of tyrosine kinases introduces the possibility that vascular
endothelial growth factor (VEGF), a key modulator of adherens junction stability that
signals through a tyrosine kinase pathway, may be involved. VEGF has been implicated
in arsenic-related toxicity through activation of PKCδ in smooth muscle cells (Soucy et
al., 2004). In addition, the VEGF receptor tyrosine kinases have been shown to signal
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with PKCα activation and downstream AKT signaling (Gliki et al., 2002). Moreover,
VEGF signals through a Ras-MEK-ERK pathway independent of PKCα suggesting that
not all As(III)-related effects may be PKCα dependent. Stress kinases such as p38 and cJun amino-terminal kinase (JNK) could also potentially be involved in the observed
effects of As(III). Barchowsky et al. (1999b) showed that high levels of As(III) can
induce cellular stress and activate stress kinases including p38. On the other hand, lower
concentrations have been shown to induce DNA synthesis and reactive oxygen species
(Barchowsky et al., 1996) without activating stress kinases (Barchowsky et al., 1999b).
The role of these alternative pathways in endothelial arsenic toxicity is the subject for
future investigations.
In summary, we have determined a potential mechanism for arsenic-induced
atherosclerosis. This study demonstrates that As(III)-induced activation of PKCα leads to
tyrosine phosphorylation of β-catenin and formation of stress fibers. Tyrosine
phosphorylation of β-catenin may cause weakening of the adherens junctions, and this
effect, in association with the contractile force generated by stress fibers, results in gap
formation and increased endothelial permeability. Proteins at the adherens junctions are
largely responsible for maintaining the barrier and normally allow passage of selected
molecules. Injury to the endothelium can promote accumulation of oxLDLs and
monocytes/macrophages in the intima of blood vessels (Lusis, 2000), ultimately leading
to formation of foam cells. The intercellular gaps and increased permeability caused by
arsenic

could

potentially

accelerate/enhance

influx

of

oxLDLs

and

monocytes/macrophages across the endothelium and contribute significantly to the
progression of atherosclerosis.
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Chapter 4
Conclusions

4.1 Conclusions
Arsenic contamination of ground water is a global problem and millions of people
worldwide are exposed to arsenic through drinking water. Arsenic exposure has been
associated with the development of cardiovascular diseases such as carotid
atherosclerosis (Wang et al., 2002), ischemic heart disease (Tseng et al., 2003) and
hypertension (Rahman et al., 1999). Atherosclerosis is the fundamental cause of major
cardiovascular diseases including ischemic heart disease, myocardial infarction and
stroke. Arsenic levels exceeding 20 ppb in drinking water have been associated with
increased mortality from various cardiovascular diseases (Engel and Smith, 1994). In
addition to the United States, other countries including Taiwan, Bangladesh, India, China,
Vietnam and Argentina have high levels of arsenic in ground water ranging from 5014,000 ppb (Wang and Wai, 2004).
Our laboratory has focused on elucidating the mechanisms of arsenic-induced
atherosclerosis. In this study, the role of arsenic in atherogenesis was determined by (1)
characterizing the time- and concentration-dependent effects of sodium arsenite [As(III)]
on the initiation and progression of atherosclerosis in ApoE-/- /LDLr-/- atherosclerotic
mouse model, (2) determining the effects of As(III)-induced peroxynitrite on the
activation of calcium dependent cPKC isotypes, α and β, in human aortic endothelial cells
and (3) determining whether activation of cPKC isotypes, α and β, by As(III) are
involved in endothelial barrier disruption.
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The time- and concentration-dependent effects of environmentally relevant
concentrations of arsenic in the development of atherosclerosis were investigated using
the ApoE-/- /LDLr-/- mouse model that is a well-established animal model of human
atherosclerosis (Ishibashi et al., 1994, Jawein et al., 2004). Atherosclerotic plaque
development was determined by measuring the percent occlusion of the innominate
artery, which is a small vessel that connects the aortic arch to the right subclavian and
right carotid arteries. Development of atherosclerotic lesions in this artery has been
shown to progress at a highly consistent rate and closely resemble that of the human
condition (Rosenfeld et al., 2000).
The temporal effects of arsenic were determined by exposing the mice to 10 ppm
As(III) in drinking water for 5 or 10 weeks. Histology revealed that mice treated with
As(III) showed an increasing trend in atherosclerotic plaque formation within the
innominate arteries compared to the controls at both 5 and 10 weeks. Analysis of IL-6
levels in the serum obtained from mice treated with As(III) for 10 weeks showed an
increasing trend compared to the control mice. These results suggest that As(III)
contributes to atherogenesis at an early stage of the disease.
The concentration-dependent effects of arsenic were analyzed by exposing the
ApoE-/- /LDLr-/- mice to 1, 5 and 10 ppm As(III) in drinking water for 20 weeks. A
significant increase in occlusion of the innominate arteries was observed with 1 and 5
ppm As(III). Our laboratory has previously shown that exposure to 10 ppm As(III) for 18
weeks significantly increases atherosclerotic plaque formation in ApoE-/- /LDLr-/- mice
(Bunderson et al., 2004). However, in this study an increasing trend in occlusion was
observed with 10 ppm As(III), and serum IL-6 levels were significantly elevated in this
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group. These results demonstrate the significance of low levels of arsenic in the onset and
progression of atherosclerosis in this animal model. Surprisingly, sVCAM-1 levels were
lower at both the 10 and 20 week time points in 10 ppm As(III) treated mice compared to
the control mice. However, this does not suggest that there is reduced expression of
endothelial VCAM-1.
The endothelium is the most important barrier between the blood and vessel wall
and it that allows passage of only selected molecules. Damage to the endothelium can
result in increased permeability and promote the accumulation of oxidized LDLs and
monocytes into the blood vessel intima. Chen et al. (2004) and Tsai et al. (2005) have
documented that As(III) increases endothelial permeability in rodents. Also, As(III)
exacerbates the development of atherosclerosis (Bunderson et al., 2004, Simeonova et al.,
2003). Therefore, a rational approach was to determine whether As(III) affects the
integrity of the endothelial monolayer.
We determined the role of PKCα and β in As(III)-mediated disruption of
endothelial monolayer integrity. The translocation of PKC from cytosol to the membrane
is an important step in its activation process (Newton, 2001). Therefore, HAECs were
exposed to 1, 5 and 10 μM As(III), and cPKC activation was analyzed at the 1-h time
point by determining the protein content in the membrane and cytosolic fractions by
Western blotting technique. Treatment with 5 and 10 μM As(III) induced a significant
increase in PKCα activation as determined by quantifying the protein content in the
membrane fraction. No change was observed with 1 μM As(III) treatment. In the
cytosolic fraction, a decrease in the PKCα content was observed with increasing As(III)
concentration indicative of PKCα translocation from the cytosol to the membrane.
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Treatment of the cells with the cPKC inhibitor, 250 nM Gö 6976, for 1 h or with the
intracellular Ca2+ chelator, 20 μM BAPTA-AM, for 30 min, prior to and during 10 μM
As(III) treatment inhibited the PKCα activation. The phorbol ester, PMA, and Ca2+
ionophore, A23187, were used as positive controls. PKCβ1 was only detected in the
cytosolic fraction and no protein was detected in the membrane fraction at the 1-h time
point. Since, no activation of PKCβ1 was detected, the effect of As(III) on PKCβ2 was not
analyzed.
As(III) treatment failed to induce generation of peroxynitrite in HAECs as
analyzed by immunofluorescence staining for 3-nitrotyrosine as well as with the
hydroethidine assay that measures the conversion of hydroethidine to its oxidized
fluorescent product ethidium. Also, pretreatment of HAECs with the peroxynitrite
decomposition catalyst, FeTPPS, or the nitric oxide synthase inhibitor, L-NAME, did not
inhibit/affect the activation of PKCα. However, a significant increase in 3-nitrotyrosine
was observed in BAECs treated with 10 μM As(III).
The integrity of the vascular endothelium is largely maintained by proteins of the
adherens junctions; VE-cadherin and β-catenin. The association of VE-cadherin with βcatenin is critical for the stability of adherens junctions, and tyrosine phosphorylation of
either one or both the proteins can alter endothelial integrity. The effect of As(III)
exposure on tyrosine phosphorylation of VE-cadherin and β-catenin was analyzed at 1 h
in HAECs by immunoprecipitation followed by Western blotting. Treatment of cells with
1 μM As(III) showed no change in tyrosine phosphorylation as compared to the control
(untreated), whereas an increasing trend in tyrosine phosphorylation was observed with 5
μM As(III), and 10 μM As(III) treatment resulted in a significant increase in tyrosine
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phosphorylation of β-catenin. The increase in tyrosine phosphorylation induced by 10 μM
As(III) was completely inhibited by 250 nM Gö 6976. No tyrosine phosphorylation of
VE-cadherin was detected. Also, no tyrosine nitration of VE-cadherin or β-catenin was
detected, which further confirmed the absence of peroxynitrite generation with As(III)
treatment.
The effect of As(III) on cell-cell adhesion was analyzed with immunofluorescence
staining for VE-cadherin. HAECs were treated with 1, 5 and 10 μM As(III) for 1, 6, 12
and 24 h. A concentration-dependent increase in gap formation and loss or non-uniform
staining of VE-cadherin was observed with As(III) treatment at all time points, and the
frequency and size of gaps observed were maximal at the 6-h time point. The cPKC
inhibitor, Gö 6976, inhibited gap formation at all concentrations of As(III) treatment, and
uniform distribution of VE-cadherin could be observed at cell-cell junctions. A similar
concentration-dependent effect of As(III) was also observed on β-catenin distribution as
analyzed at the 6-h time point. The frequency of gap formation was greater with 10 μM
As(III) than with 1 and 5 μM As(III), and non-uniform distribution or loss of β-catenin
staining was evident wherever gaps could be observed. Also, 250 nM Gö 6976 treatment
inhibited the gap formation induced by 10 μM As(III) and restored the β-catenin staining
at cell-cell junctions.
Analysis of the effect of As(III) treatment on VE-cadherin protein content at the
24-h time point revealed approximately 8, 15 and 30% reductions in VE-cadherin protein
with 1, 5 and 10 μM As(III) treatment, respectively. Protein content was analyzed by
Western blotting.
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The cadherin/catenin complex associates with the actin cytoskeleton, which is
crucial for maintaining junctional stability and structural integrity of the endothelial cell
monolayer. Reorganization of actin microfilaments into stress fibers can adversely affect
monolayer integrity, since it can lead to dissociation of the cadherin/catenin complex
from the actin cytoskeleton. The effects of 1, 5 and 10 μM As(III) on reorganization of
actin microfilaments were analyzed at 1, 6, 12 and 24 h by immunofluorescence staining
using fluorophore-conjugated phalloidin. A concentration-dependent increase in stress
fiber formation was observed with As(III) treatment at all time points, and the density of
stress fibers observed was maximal at the 6-h time point. The cPKC inhibitor, Gö 6976,
inhibited/reduced stress fiber formation at all concentrations of As(III) treatment.
As(III) treatment resulted in gap formation and stress fiber formation that was
maximal at the 6-h time point. Hence, the effect of 1, 5 and 10 μM As(III) treatment on
endothelial permeability was analyzed at the 6-h time point. A 5% increase in
permeability was observed with 1 and 5 μM As(III) treatment, whereas 10 μM As(III)
induced approximately a 19% increase. Treatment with 250 nM Gö 6976 inhibited the
increase in permeability induced by 10 μM As(III).
Taken together, this study demonstrates that As(III) induces activation of PKCα
without peroxynitrite formation in HAECs. No activation of PKCβ was observed at the
time point analyzed. As(III)-induced activation of PKCα leads to tyrosine
phosphorylation of β-catenin and formation of stress fibers. Tyrosine phosphorylation of
β-catenin may cause weakening of the adherens junctions, and this effect, in association
with the contractile force generated by stress fibers, results in gap formation and
increased endothelial permeability. The intercellular gaps and increased permeability
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caused by As(III) could potentially accelerate/enhance influx of oxLDLs and
monocytes/macrophages across the endothelium and contribute significantly to the
progression of atherosclerosis. Accordingly, environmentally relevant concentrations of
arsenic induce significant increases in atherosclerotic plaque formation in the ApoE-//LDLr-/- mouse. The process of atherosclerosis is plausibly initiated or accelerated by
arsenic at an early stage. The arsenic-induced, cPKC-dependent, signaling pathway
mediating endothelial barrier disruption is outlined in Fig. 31.
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Fig. 31. Schematic of arsenic mediated endothelial disruption and development of
atherosclerosis
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4.2

Future Directions
The increase in vascular permeability with arsenic treatment has been

demonstrated in vivo in rodents (Chen et al., 2004, Tsai et al., 2005). Visualization of
stress fiber formation as well as cell retraction or gap formation after arsenic treatment in
vivo will provide affirmation to the in vitro effects observed. Our study demonstrated
PKCα mediated disruption of the endothelial monolayer. Arsenic is a versatile molecule
and affects signaling pathways in multiple ways. The mechanism(s) of arsenic-induced
activation of PKCα needs to be elucidated. PKC is a very important signaling molecule
that has a host of cellular substrates and plays an important role in several physiological
and pathological processes. Determining the specific substrate(s) of PKCα that mediates
downstream tyrosine phosphorylation of adherens junction proteins and endothelial
disruption will be crucial. This will help in designing specific pharmacological
intervention strategies without affecting other physiological processes.
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Chapter 5
Role of Arsenic in Endothelial Cell Activation and Uptake of Modified
Lipids by Macrophages

5.1 Objective
Atherosclerosis is an inflammatory disease, initiated by activation of the
endothelium and characterized by expression of cell adhesion molecules and secretion of
proinflammatory cytokines and chemokines. These events promote the transmigration of
leukocytes into the subendothelial matrix, resulting in the growth of atheroma. The
objective of this study was to determine whether arsenic induces endothelial cell
activation and promotes uptake of modified lipids by macrophages, thereby mimicking
the events of the initiation and progression of the atherosclerotic disease processes.

5.2 Introduction
Atherogenesis begins with the endothelial cells lining the vessel wall. Activated
endothelial cells express cell adhesion molecules such as E-selectin, intercellular cell
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Eselectin is involved with the rolling and tethering of leukocytes to the activated
endothelium, whereas ICAM-1 and VCAM-1 promote firm adhesion of leukocytes via
interaction with the integrin molecules expressed on leukocytes (Blankenberg et al.,
2003). In particular, VCAM-1 and not ICAM-1 has been demonstrated to function
primarily in monocyte recruitment to the blood vessel intima (Cybulsky et al., 2001). In
addition to the cell adhesion molecules, proinflammatory cytokines such as interleukin-1

161

(IL-1), IL-6, macrophage colony-stimulating factor (M-CSF), granulocyte macrophage
colony-stimulating factor (GM-CSF) and tumor necrosis factor α (TNFα) produced by
various cell types such as endothelial cells, macrophages and smooth muscle cells play an
important role in the atherosclerotic process (Tedgui and Mallat, 2006) by instigating a
self-perpetuating inflammatory process.
The cytokine, M-CSF, stimulates the differentiation of monocytes into
macrophages in the subendothelium as well as expression of macrophage scavenger
receptors (Lusis, 2000). The uptake of modified low density lipoproteins (LDL) by
resident macrophages is mediated by scavenger receptors. Class A scavenger receptor,
SR-A, and class B scavenger receptor, CD36, are the two scavenger receptors of primary
importance. It has been demonstrated that SR-A and CD36, together, are responsible for
uptake of the majority of modified LDLs by macrophages (Kunjathoor et al., 2002). The
uptake of these modified LDLs by resident macrophages leads to formation of lipid-laden
macrophages known as foam cells. In vivo studies have demonstrated that mice lacking
either of these scavenger receptors show a reduction in atherosclerotic lesions (Suzuki et
al., 1997, Febbraio et al., 2000).
Conflicting results have been documented regarding the effects of arsenic on IL-6
production. In vitro experiments suggest that high concentration of arsenic inhibits IL-6
production (Hershko et al., 2002), whereas in vivo studies have demonstrated increased
IL-6 production with arsenic treatment (Liu et al., 2000). Evidence showing a clear and
direct relationship between arsenic exposure and expression of cell adhesion molecules,
an indicator of endothelial activation, was lacking when our study was proposed.
However, Tsou et al. (2005) have since shown that arsenic enhances TNFα-induced
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expression of VCAM-1. The effect of arsenic on the uptake of modified lipids by
macrophages also remains unknown. Therefore, the objective of this study was to
determine whether arsenic modulates the process of atherosclerosis at an early stage
using an in vitro cell system.

5.3 Materials and Methods
5.3.1

Cell culture. Human aortic endothelial cells (HAECs) were purchased from

Cambrex Bio Science (Walkersville, MD) and were grown in the supplier’s formulated
medium:

EBM-2

medium

supplemented

with

EGM-2

SingleQuots

(0.04%

hydrocortisone, 0.4% hFGF-B, 2% FBS and 0.1% each of VEGF, R3-IGF-1, ascorbic
acid, heparin, hEGF and GA-1000). Bovine aortic endothelial cells (BAECs) were
provided by Dr. J. Douglas Coffin of The University of Montana, Missoula and were
originally a gift from Dr. Steve Schwartz of The University of Washington. Cells were
grown in Dulbecco’s Modified Eagle Medium (DMEM) with penicillin/streptomycin and
L-glutamine, and supplemented with 15% FBS (Mediatech, Inc., Herndon, VA).
Endothelial cells were used between passages 2 and 10. The human monocytes, THP-1
cells, were a gift from Dr. Elizabeth Putnam of The University of Montana, Missoula and
were grown in suspension in RPMI 1640 medium (Mediatech, Inc., Herndon, VA)
containing 2 mM L-glutamine, 10 mM HEPES and 1.5 g/l sodium bicarbonate, and
adjusted to contain 4.5 g/l glucose, 1.0 mM sodium pyruvate, 0.05 mM 2mercaptoethanol and 10% FBS (Mediatech, Inc., Herndon, VA). The mouse
macrophages, RAW 264.7 cells, were a gift from Dr. Andrij Holian of The University of
Montana, Missoula and were grown in DMEM with penicillin/streptomycin and L-
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glutamine, and supplemented with 10% FBS. Cells were incubated at 37 0C under a
humidified atmosphere containing 5% CO2.

5.3.2

Enzyme-linked immunosorbent assay. HAECs were seeded at a density of

5x104 or 1x105 cells/well in 24-well plates for 24-48 h. Confluent cells were treated with
1, 5 and 10 μM As(III) (GFS Chemicals, Columbus, OH) for 1, 6, 12, 24 and 48 h. After
respective time points, medium containing As(III) was removed and cells were exposed
to fresh medium without As(III) for 24 h. IL-6 released in the medium without As(III)
was assayed by ELISA (BD biosciences, San Diego, CA) according to manufacturer’s
instructions.

5.3.3

Flow cytometric analysis of VCAM-1 expression. HAECs were seeded at a

density of 1x106 cells/flask in 25 cm2 cell culture flasks for 48 h. Confluent cells were
treated in serum free medium with 1, 5 and 10 μM As(III) for 24 h. Cells were
trypsinized using trypsin (0.025%)/EDTA (0.01%) solution (Cambrex Bio Science,
Walkersville, MD). This concentration of trypsin/EDTA has been shown not to affect the
VCAM-1 protein during trypsinization (Zhang and Frei, 2002, van der Zijpp et al., 2003).
Cells were collected by centrifugation and resuspended in phosphate buffered saline
(PBS)/5% FBS solution. Cells were incubated with allophycocyanin (APC)-conjugated
mouse anti-human VCAM-1 monoclonal antibody (concentration = 20 μl/106 cells) (BD
Biosciences, San Diego, CA) for 45 min at 4 oC. Cells were then rinsed twice with PBS
and fluorescence was analyzed using Becton Dickinson (BD) Facs Aria flow cytometer
(San Jose, CA). A total of 10,000-30,000 viable cells were analyzed per experimental
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sample. Data were analyzed using BD Facsdiva software. Background binding was
detected using an APC-conjugated mouse IgG isotype control (BD Biosciences, San
Diego, CA).

5.3.4

Flow cytometric analysis of lipid uptake by macrophages. The effect of serum

obtained from ApoE-/- /LDLr-/- mice on the uptake of acetylated LDL by RAW 264.7
macrophage cells was analyzed by flow cytometry. Mice were obtained from Jackson
Laboratories (Bar Harbor, ME). All the animals were housed under specific pathogenfree conditions according to IACUC protocols with 12 h light/dark cycle and controlled
temperature. ApoE-/- /LDLr-/- mice receiving arsenic treatment were given 1 or 10 ppm
As(III) for 18 weeks ad libitum via drinking water. The control group received ddH2O.
The mice were fed a commercial mouse chow diet. Blood was collected from these mice
at the end of treatment periods and serum was obtained by centrifugation of the blood at
1,600 rpm for 5 min at 4 0C and was stored at -80 0C. The treatment of mice with As(III)
and blood collection was done by former graduate student in our laboratory for other
experiments. A solution of 15% mouse serum was made with DMEM and 1 ml of this
serum solution was exposed to 1x106 RAW 264.7 cells for 24 h at 37 oC. After 22 h of
incubation, 1 μg/ml fluorescein isothiocyanate (FITC)-conjugated acetylated LDL
(Molecular Probes, Inc. Eugene, OR) was added to each tube and incubated for 2 h at 37
o

C. Cells were rinsed with PBS and fluorescence was analyzed using the flow cytometer

as mentioned above using appropriate controls.
To determine the uptake of acetylated LDLs by RAW 264.7 cells exposed to
conditioned medium from BAECs and the role of the scavenger receptor, SR-A, in LDL
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uptake, BAECs were seeded at a density of 5x105 cells/well in 6-well plates for 24 h.
Cells were treated with 10 μM As(III) for 48 h. Medium containing As(III) was removed
after 48 h and cells were incubated with serum free medium without As(III) for 24 h.
RAW 264.7 cells (1x106) were exposed to 1 ml of the BAEC conditioned medium
without As(III) for 24 h at 37 0C. After 21 h of incubation, the SR-A blocking antibody,
2F8 (8 μg/ml), was added wherever necessary and after 22 h, 1 μg/ml FITC-conjugated
acetylated LDL was added to each tube. Cells were rinsed with PBS and fluorescence
was analyzed using the flow cytometer as mentioned above using appropriate controls.
To determine the effective concentration of 2F8 antibody in blocking SR-A, RAW 264.7
cells were incubated with varying concentrations of 2F8 antibody for 45 min followed by
incubation with 1 μg/ml FITC-conjugated acetylated LDL for 2 h at 37 0C. Cells were
rinsed with PBS and acetylated LDL uptake was analyzed by flow cytometry.
To determine the uptake of acetylated LDLs by THP-1 cells exposed to conditioned
medium from HAECs, HAECs were seeded at a density of 1x106 cells/flask in 25 cm2
cell culture flask for 48 h. Confluent cells were treated with 1, 5 and 10 μM As(III) for 24
and 48 h. After respective time points, medium containing As(III) was removed and cells
were exposed to fresh medium without As(III) for 24 h. Differentiated THP-1 cells
(1x106) were exposed to 1 ml of the HAEC conditioned medium without As(III) for 24 h
at 37 0C. THP-1 cells were differentiated using 33 μg/ml Phorbol 12-Myristate 13Acetate (PMA) (Sigma-Aldrich, Saint Louis, Missouri). After 22 h of incubation, 1 μg/ml
FITC-conjugated acetylated LDL was added to each tube and incubated for 2 h. Cells
were rinsed with PBS and acetylated LDL uptake was analyzed by flow cytometry.
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5.3.5

Statistical analysis. Results are presented as mean ± standard error of the mean

(SEM). When required, data was normalized with its respective control in order to
exclude differences in background conditions. Statistical analysis was performed using
Student’s t test when comparing two groups or Bonferroni method for comparing three
groups or more. When using the Bonferroni method, the alpha level of each individual
test was adjusted downwards to ensure that the overall experiment wise-risk remains at
0.05. Statistical analysis was performed using GraphPad Prism, version 4.00. Alpha error
was set at p<0.05.

5.4 Results
5.4.1

Effect of As(III) on endothelial VCAM-1 expression

VCAM-1 mediates firm adhesion of leukocytes to the endothelium and transmigration
into the blood vessel intima (Blankenberg et al., 2003, Cybulsky et al., 2001). Therefore,
we analyzed the effect of As(III) on endothelial VCAM-1 expression by flow cytometry.
HAECs were exposed to 1, 5 and 10 μM As(III) for 24 h. No change in VCAM-1
expression was observed with As(III) treatment (Fig. 32).

5.4.2

Effect of As(III) on IL-6 secretion

The proinflammatory cytokine, IL-6, plays an important role in the development of
atherosclerosis (Tedgui and Mallat, 2006). HAECs were exposed to 1, 5 and 10 μM
As(III) for 1, 6, 12, 24 and 48 h. After the respective time points, As(III) containing
medium was replaced with regular medium without As(III) for 24 h, and IL-6 levels were
analyzed in medium without As(III) by ELISA. A concentration-dependent decrease in
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IL-6 levels was observed with As(III) treatments compared to respective controls at most
time points (Fig. 33).

5.4.3

Acetylated LDL uptake by RAW 264.7 cells exposed to mouse serum

Following transmigration of monocytes into the blood vessel intima, the monocytes are
differentiated into macrophages and take up modified LDLs leading to formation of foam
cells (Lusis, 2000). We therefore analyzed whether serum from As(III) treated mice could
promote the uptake of acetylated LDLs by mouse macrophages, RAW 264.7 cells, using
flow cytometry. Serum was obtained from mice treated with 1 and 10 ppm As(III) in
drinking water for 18 weeks. Exposure of RAW 264.7 cells to serum from 1 ppm As(III)
treated mice resulted in a significant increase in acetylated LDL uptake (Fig. 34A),
whereas serum from 10 ppm As(III) treated mice showed an increasing trend (Fig. 34B).

5.4.4

Acetylated LDL uptake by RAW 264.7 cells exposed to conditioned medium

from As(III)-treated BAECs and the role of SR-A in LDL uptake.
The role of the scavenger receptor, SR-A, expressed by RAW 264.7 cells in the uptake
acetylated LDL was analyzed by treating cells with increasing concentration (1, 2, 4, 8
and 10 μg/ml) of the SR-A blocking antibody, 2F8. A concentration-dependent decrease
in acetylated LDL uptake was observed with increasing concentration of 2F8 antibody
(Fig. 35A). In further experiments 8 μg/ml concentration of 2F8 antibody was used.
To analyze the effect of As(III) on the uptake of acetylated LDLs by RAW 264.7
cells, BAECs were exposed to 10 μM As(III) for 48 h, after which the As(III) containing
medium was replaced with serum free medium without As(III) for 24 h. RAW 264.7 cells
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were exposed to the conditioned medium from BAECs and an increasing trend in
acetylated LDL uptake was observed (Fig. 35B). The acetylated LDL uptake was
inhibited by pretreatment of RAW 264.7 cells with 2F8 antibody (Fig. 35B).

5.4.5

Acetylated LDL uptake by THP-1 cells exposed to conditioned medium from

As(III)-treated HAECs
The effect of As(III) on acetylated LDL uptake was also analyzed using a human cell
system. HAECs were exposed to 1, 5 and 10 μM As(III) for 24 and 48 h. After the
respective time points, As(III) containing medium was replaced with regular medium
without As(III) for 24 h, and uptake of acetylated LDLs by differentiated THP-1 cells
was analyzed using the conditioned medium. At the 24-h time point, differentiated THP-1
cells showed an increasing trend in acetylated LDL uptake with 5 μM As(III), whereas a
decreasing trend was observed with 10 μM As(III) (Fig. 36A). At the 48-h time point,
exposure of differentiated THP-1 cells to the conditioned medium showed an increasing
trend in acetylated LDL uptake with 1 μM As(III), whereas a decreasing trend was
observed with 10 μM As(III) (Fig. 36B).
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5.5 Figures
Fig. 32. Effect of As(III) on endothelial VCAM-1 expression

Fig. 32. Effect of As(III) on endothelial VCAM-1 expression. Confluent HAECs were
treated with 1, 5 and 10 μM As(III) for 24 h and VCAM-1 expression was analyzed by
flow cytometry using an APC-conjugated anti-VCAM-1 antibody.

170

Fig. 33. Effect of As(III) on IL-6 secretion

Fig. 33. Effect of As(III) on IL-6 secretion. Confluent HAECs were treated with 1, 5 and
10 μM As(III) for 1, 6, 12, 24 and 48 h. After the respective time points, As(III)
containing medium was replaced with medium without As(III) for 24 h. IL-6 levels were
measured by ELISA in the medium without As(III). Treatment groups marked with
asterisks were significantly different from the respective controls (*, p<0.05). The control
(100%) is indicated by dotted line. Error bars represent mean ± SEM for n=3-5
experiments.
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Fig. 34. Acetylated LDL uptake by RAW 264.7 cells exposed to mouse serum
A.

B.

Fig. 34. Acetylated LDL uptake by RAW 264.7 cells exposed to mouse serum. RAW
264.7 cells were exposed to 15% serum from mice treated with 1 ppm (A) and 10 ppm
(B) As(III) for 18 weeks. Treatment group marked with asterisk was significantly
different from the control (*, p<0.05). Error bars represent mean ± SEM for (A) n=8
mice, (B) n=5 mice per group.
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Fig. 35. Acetylated LDL uptake by RAW 264.7 cells exposed to conditioned medium
from As(III)-treated BAECs and the role of SR-A in LDL uptake
A.

B.

Fig. 35. Acetylated LDL uptake by RAW 264.7 cells exposed to conditioned medium
from As(III)-treated BAECs and the role of SR-A in LDL uptake. The concentrationdependent inhibition of acetylated LDL uptake by RAW 264.7 cells was analyzed using
the 2F8 antibody, n=1 (A). BAECs were treated with 10 μM As(III) for 48 h and As(III)
containing medium was replaced with medium without As(III) for 24 h. Acetylated LDL
uptake by RAW 264.7 cells was analyzed using the conditioned medium (B). The control
(100%) is indicated by dotted line in (B). Error bars represent mean ± SEM for n=3-4
experiments. Treatment group marked with * and # was significantly different from the
control and As(III) treated group, respectively, with p<0.001.
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Fig. 36. Acetylated LDL uptake by THP-1 cells exposed to conditioned medium
from As(III)-treated HAECs
A.

B.

Fig. 36. Acetylated LDL uptake by THP-1 cells exposed to conditioned medium from
As(III)-treated HAECs. Confluent HAECs were treated with 1, 5 and 10 μM As(III) for
24 and 48 h. After the respective time points, As(III) containing medium was replaced
with medium without As(III) for 24 h. Acetylated LDL uptake by differentiated THP-1
cells was analyzed using the conditioned medium at the 24-h time point (A) and 48-h
time point (B). The control (100%) is indicated by dotted line in (A and B). Error bars
represent mean ± SEM for n=3 experiments.
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5.6 Discussion
Arsenic has been associated with the development of atherosclerosis in
epidemiological and animal studies (Bunderson et al., 2004, Simeonova et al., 2003,
Wang et al., 2002). In vitro studies have suggested several possible mechanisms for the
development of cardiovascular diseases such as atherosclerosis (Navas-Acien et al.,
2005). We therefore investigated whether arsenic induces endothelial cell activation and
promotes uptake of modified lipids by macrophages, thereby mimicking the events in the
initiation and progression of the atherosclerotic disease processes. The results of this
study suggest that As(III) alone does not induce the expression of the cell adhesion
molecule, VCAM-1, or proinflammatiry cytokine, IL-6, in HAECs. Also, no clear
evidence was obtained regarding the effects of As(III) on uptake of modified lipids by
macrophages.
The VCAM-1 gene is regulated by multiple transcription factors such as nuclear
factor-kappa B (NF-κB), activator protein-1 (AP-1), interferon regulatory factor-1 (IRF1) and Sp-1 (Lechleitner et al., 1998, Neish et al., 1995, Neish et al., 1992, Tsou et al.,
2005). Similarly, the IL-6 gene is regulated by multiple transcription factors such as NFκB, AP-1, C/EBP and CREB (Hershko et al., 2002). NF-κB is considered to be most
important in the regulation of VCAM-1 and IL-6 expression. In vitro studies suggest that
low levels of As(III) (1-5 μM) activate NF-κB (Barchowsky et al., 1996), whereas high
As(III) levels (500 μM) inihibit NF-κB activation (Roussel and Barchowsky, 2000,
Hershko et al., 2002). Consistent with this, Hershko et al. (2002) demonstrated that 500
μM As(III) treatment inhibits IL-1β-induced IL-6 expression in enterocytes. Although in
theory the As(III) concentrations used in the present study should activate NF-κB and
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induce IL-6 production, no such outcome was observed. In vivo studies using mouse
models, however, suggest that arsenic exposure increases serum IL-6 levels (Liu et al.,
2000, Chapter 2 of this dissertation). Also, in our study no VCAM-1 expression was
observed with As(III) treatment. A similar effect of 10 μM As(III) on VCAM-1
expression was documented by Tsou et al. (2005), where As(III) treatment alone did not
induce VCAM-1 expression, but potentiated TNFα-induced VCAM-1 expression. This
suggests that As(III) by itself does not induce cell adhesion molecule expression, but in
the presence of other inflammatory cues may enhance the process. Simeonova et al.
(2003) have demonstrated increased IL-8 mRNA levels with 5 μM As(III) treatment in
HAECs. Therefore, it may be possible that arsenic treatment alone may induce only
certain inflammatory mediators and exacerbate the effect of others.
Exposure of RAW 264.7 macrophages to conditioned medium from BAECs
showed only a modest increasing trend in acetylated LDL uptake with As(III) treatment.
The majority of the uptake was mediated by SR-A, which is in sync with other studies
(Kunjathoor et al., 2002). Also, no specific effect in acetylated LDL uptake with As(III)
treatment was observed using the THP-1/HAEC cell system. However, a significant
increase in acetylated LDL uptake was observed with serum from 1 ppm As(III)-treated
mice. This suggests that in vivo inflammatory conditions may influence the uptake of
modified lipids that may not be possible to replicate in vitro. Exposure of macrophages to
serum from 10 ppm As(III)-treated mice revealed only an increasing trend in acetylated
LDL uptake. The reason for this finding is unclear.
The process of atherosclerosis is regulated by different inflammatory mediators
secreted by several different cell types such as endothelial cells, leukocytes and smooth
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muscle cells. Inflammatory mediators such as cytokines regulate the activity of cells in an
autocrine or paracrine fashion and can trigger several different cellular responses
depending on the timing and context. For example, the expression of cell adhesion
molecules by endothelial cells is regulated by cytokines such as IL-6, IL-1β and TNFα
(McDouall et al., 2001, Watson et al., 1996) that are secreted by macrophages, smooth
muscle cells and/or endothelial cells, simultaneously or in unique temporal and spatial
context. Consistent with this, it has been shown that 5 μM As(III) treatment induces IL-6
and monocyte chemoattractant protein-1 (MCP-1) expression in human smooth muscle
cells (Lee et al., 2005). Therefore, stimulatory signals to the endothelial cells from other
cell types such as smooth muscle cells could be crucial. This makes it difficult to mimic
in vivo atherosclerotic conditions in in vitro settings. Endothelial and smooth muscle cells
in the vasculature along with resident macrophages play significant roles in the process of
atherosclerosis. Therefore, co-culture experiments may more adequately reflect in vivo
conditions during atherogenesis. In summary, arsenic did not increase the expression of
VCAM-1 and IL-6 by itself, and the effects of arsenic on the uptake of modified lipids
remain unclear in our experimental setting.
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